US.ABBV · AbbVie

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.541660742835011,
        "turnoverUsdM": 1322.8274503110001,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.ABBV",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 271.12,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.1,
      "take_profit_price": 300.8134,
      "target_multiplier": 1.9,
      "technical_strength": 1.65,
      "take_profit_percent": 5.3
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.083321485670022,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 61.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 54.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 275.089,
    "ma50": 266.1246,
    "close": 285.64,
    "prevClose": 285.19,
    "avgVolume20": 5301940,
    "volumeRatio": 0.87,
    "changePercent": 0.16
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.0007707938907297596,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.8910408174848795,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.6688888849276731,
      "volat_points": 0,
      "day_range_pct": 0.01564906821001731,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 61.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 46,
        "contribution": 2.3
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 7,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 46.67,
        "contribution": 7
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 19.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 66,
        "contribution": 19.8
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 54.3,
    "details": [
      "基本面分析總分: 2.3/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 7/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 19.8/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.3,
      "資金流": 13.2,
      "市場環境": 7,
      "情緒分析": 3,
      "技術信號": 19.8,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.3,
          "marginPoints": 0,
          "turnoverUsdM": 1322.8274503110001,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.ABBV",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 735.23500335,
                "ma50": 725.8121993399999,
                "name": "QQQ",
                "close": 704.40002,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.1504974000001,
                "ma50": 767.8083956999998,
                "name": "SPY",
                "close": 759.96997,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.541660742835011,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143139491,
                "url": "https://finnhub.io/api/news?id=2958cd97c7b4f36325b485f8fbddae3cb108877b498a65426abd76446385dff9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie’s analyst narrative has shifted again, with fair value in one model now set at US$284.79 compared with US$278.61 previously, and other price targets clustering in a wide US$260 to US$325 range. Recent commentary links these higher targets to confidence in AbbVie’s portfolio across immunology, neuroscience and oncology, while still flagging risks around specific programs and crowded positioning. As you read on, you will see how to interpret these moving targets and track the story as it...",
                "category": "company",
                "datetime": 1792800841,
                "headline": "AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases"
              },
              {
                "id": 143135643,
                "url": "https://finnhub.io/api/news?id=f26567bd7f85fdef5ceef3c9708a46d9985e54622b931c2efbc21984aa7f174b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.",
                "category": "company",
                "datetime": 1792766160,
                "headline": "BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?"
              },
              {
                "id": 143135623,
                "url": "https://finnhub.io/api/news?id=5bd6437a7982a0f4e5e276aa85fc42ac12edb2e613dcd781373c7346252bea15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792760408,
                "headline": "AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"
              },
              {
                "id": 143100075,
                "url": "https://finnhub.io/api/news?id=0256d33f2772215091f048d1cbd78eac61299f173ffcfa2e6c21eaddd5090bbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1792672203,
                "headline": "AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?"
              },
              {
                "id": 143071295,
                "url": "https://finnhub.io/api/news?id=a0557876049c892b1e60e52e6bcc47345c2aa86dfc6f6c29d0ec47c25f582741",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The latest trading day saw AbbVie (ABBV) settling at $284.8, representing a -1.48% change from its previous close.",
                "category": "company",
                "datetime": 1792615504,
                "headline": "AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors"
              },
              {
                "id": 143008516,
                "url": "https://finnhub.io/api/news?id=375b638b7eaf2da6bdc2c49f84cac71f9af6720efd645a54ef438ec519348a20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) reported new Phase 2a data for ABBV-466 in Crohn's disease at recent major medical meetings. The dual-targeting ABBV-466 therapy produced higher endoscopic remission rates than single-pathway treatments in the Phase 2a study. Management flagged multiple new and updated presentations on its solid tumor pipeline for the 2026 ESMO Congress. The ABBV-466 Crohn's data and upcoming oncology results only capture part of what investors may want to assess on AbbVie today. Take a...",
                "category": "company",
                "datetime": 1792422942,
                "headline": "AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts"
              },
              {
                "id": 143000058,
                "url": "https://finnhub.io/api/news?id=d06b65f833a91e459cf70b016be92fb549f147c666cf3a81ffd957e6c178d086",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remissiona at Week 12 than either monotherapy in patients with Crohn's disease (CD). The difference in endoscopic remissiona rates between ABBV-466 and monotherapy groups further increased at Week 24. The findings are from the TARGET-CD study, an ongoing open-label, treat-through, Phase 2a platform study in patients wit",
                "category": "company",
                "datetime": 1792396800,
                "headline": "AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease"
              },
              {
                "id": 143007606,
                "url": "https://finnhub.io/api/news?id=4d995477e520f3dab2265e86d0ff402482a2d50bb9aee82d3847394c8885bc9e",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation",
                "category": "company",
                "datetime": 1792378285,
                "headline": "Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients"
              }
            ],
            "raw_source": [
              {
                "id": 143179729,
                "url": "https://finnhub.io/api/news?id=c445e63593ddae017438db65d785f64622a4901f01875a722b3d91243f3cb4d5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255788088/image_2255788088.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Preview this blockbuster market week: Fed decision, GDP, core PCE, and Big Tech earnings from Microsoft, Alphabet, Amazon.",
                "category": "company",
                "datetime": 1792911546,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 143167978,
                "url": "https://finnhub.io/api/news?id=7ec8c95a6a84f15e58234fd1bc8c23b98736e9284c0c77d964a6f90eb183a256",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Key Stats for AbbVie StockCurrent Price: $285. 64Target Price (Mid): ~$364Street Target: ~$285Potential Total Return: ~27%Annualized IRR: ~6% / year__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__ >>> What Happened?AbbVie (ABBV) now lets Crohn’s patients start Skyrizi at home, and when that reaches sales depends on how fast insurers move.",
                "category": "company",
                "datetime": 1792873465,
                "headline": "AbbVie Won FDA Approval for At-Home Skyrizi Starts in Crohn’s. Here’s When It Should Show Up in Sales"
              },
              {
                "id": 143165028,
                "url": "https://finnhub.io/api/news?id=53ac13576c8631a6302c4fb020ea5d83e6e1c2e792591ef99f429680b275bace",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Preview the week ahead with the Fed decision, Q3 GDP, and Big Tech earnings in focus. Read here for more details.",
                "category": "company",
                "datetime": 1792843247,
                "headline": "Fed Decision, Microsoft, Alphabet Earnings Highlight Blockbuster Week"
              },
              {
                "id": 143139491,
                "url": "https://finnhub.io/api/news?id=2958cd97c7b4f36325b485f8fbddae3cb108877b498a65426abd76446385dff9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie’s analyst narrative has shifted again, with fair value in one model now set at US$284.79 compared with US$278.61 previously, and other price targets clustering in a wide US$260 to US$325 range. Recent commentary links these higher targets to confidence in AbbVie’s portfolio across immunology, neuroscience and oncology, while still flagging risks around specific programs and crowded positioning. As you read on, you will see how to interpret these moving targets and track the story as it...",
                "category": "company",
                "datetime": 1792800841,
                "headline": "AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases"
              },
              {
                "id": 143136705,
                "url": "https://finnhub.io/api/news?id=c921b931c67960e1c3d00fc3a45f7743756b8df123bc9fd446e5a10fc913fc79",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now have the option to start SKYRIZI treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment.",
                "category": "company",
                "datetime": 1792783980,
                "headline": "U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease"
              },
              {
                "id": 143136706,
                "url": "https://finnhub.io/api/news?id=d385d0367b432398a06e8239b3eaa57779475a38f37b07323817f3edd33f2db5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge varies far more than the yields suggest.",
                "category": "company",
                "datetime": 1792782959,
                "headline": "AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?"
              },
              {
                "id": 143165976,
                "url": "https://finnhub.io/api/news?id=5d19c0417a525906e9bd5ba483e8a7499957af53f3c069f58740d501fc9bbd53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Key TakeawaysEli Lilly stock rose 10% in the week through Tuesday’s close to a record, while the S&P 500 fell 1. 1% and the Nasdaq 100 fell 3.",
                "category": "company",
                "datetime": 1792779382,
                "headline": "Eli Lilly Gained 10% in a Week to a New 52-Week High. Is There Room to Run?"
              },
              {
                "id": 143136247,
                "url": "https://finnhub.io/api/news?id=abc8806fb03ae6aac8e2e6124c786823f98383f8d2b8bdb9442e05884f80c76d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades. The question is whether their free cash flow can keep that streak alive.",
                "category": "company",
                "datetime": 1792777535,
                "headline": "Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different"
              },
              {
                "id": 143163340,
                "url": "https://finnhub.io/api/news?id=4059cbf89b91bf587bbdc7a5249918697f044c379d1d5293bd125b50288e62b6",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's",
                "category": "company",
                "datetime": 1792769783,
                "headline": "AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease"
              },
              {
                "id": 143135643,
                "url": "https://finnhub.io/api/news?id=f26567bd7f85fdef5ceef3c9708a46d9985e54622b931c2efbc21984aa7f174b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.",
                "category": "company",
                "datetime": 1792766160,
                "headline": "BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?"
              },
              {
                "id": 143163341,
                "url": "https://finnhub.io/api/news?id=c65bdef81050fbacfc5b02ebd1e64324eef7aac5e811d67840212fb5249a90cb",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Goldman Sachs  analyst Asad Haider    maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $258 to $294.",
                "category": "company",
                "datetime": 1792764071,
                "headline": "Goldman Sachs Maintains Neutral on AbbVie, Raises Price Target to $294"
              },
              {
                "id": 143133410,
                "url": "https://finnhub.io/api/news?id=a09272192ee4bb502bed8a7657ed02794d6b2c30eb4793f58babb16bbd76a6d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The global dental soft tissue wound care market is projected to grow from nearly $180 million in 2025 to nearly $390 million by 2032, a new Research and Markets report finds, with ZimVie leading ahead of AbbVie and Henry Schein, though cost sensitivity and limited reimbursement persist.Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- \"Dental Soft Tissue Wound Care Market Size, Share, & Trends Analysis | Global | 2026-2032 | Includes: Plug Dental Wound Care, Tape Dental Wound Care, and Foam Dental Wound",
                "category": "company",
                "datetime": 1792762560,
                "headline": "Global Dental Soft Tissue Wound Care Market Size, Share, and Forecast by Product, 2026-2032 | Plug, Tape, and Foam Demand to Drive 11.8% CAGR and a $390 Million Market"
              },
              {
                "id": 143135623,
                "url": "https://finnhub.io/api/news?id=5bd6437a7982a0f4e5e276aa85fc42ac12edb2e613dcd781373c7346252bea15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792760408,
                "headline": "AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release"
              },
              {
                "id": 143132272,
                "url": "https://finnhub.io/api/news?id=a05c8cee65c8b8218dcc643a6222573bc978a7fdda4e0adebb0c07d61a100c98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "This late-stage readout comes as companies explore the potential of novel mechanisms of action in HS.",
                "category": "company",
                "datetime": 1792755553,
                "headline": "AbbVie’s skin disease drug posts Phase III win as market competition heats up"
              },
              {
                "id": 143161698,
                "url": "https://finnhub.io/api/news?id=53b990e2048d7e7733dfa3e1a181d1e1577ec4db3f25cb142d68d0c34ca94e0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.",
                "category": "company",
                "datetime": 1792754700,
                "headline": "3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach"
              },
              {
                "id": 143129947,
                "url": "https://finnhub.io/api/news?id=dd1033de1a38808c96bfaf9f76cf0ea22287ed9a1757cd789080f8438e109cdc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792750443,
                "headline": "What Sent Eli Lilly Stock Higher Over The Past Year?"
              },
              {
                "id": 143106842,
                "url": "https://finnhub.io/api/news?id=e1cb5a25981342f9c599c8bdabc79af4d8976b99945110614b8bd9900fca9fee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "They definitely matter... up to a point.",
                "category": "company",
                "datetime": 1792714800,
                "headline": "What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer"
              },
              {
                "id": 143104024,
                "url": "https://finnhub.io/api/news?id=a3f737b8b032a83800fff14cb3cfba6cfd5655c0f3a9b5c515050071a886d12d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The company is gearing up for future major patent cliffs.",
                "category": "company",
                "datetime": 1792703341,
                "headline": "Great News for AbbVie Stock Investors"
              },
              {
                "id": 143135642,
                "url": "https://finnhub.io/api/news?id=87a83cd53df61e7f4dfad3340d31782e0e0cd80c44b436b7d70fd4940564b2fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Key TakeawaysAbbVie’s lutikizumab met its Phase 3 goal in hidradenitis suppurativa, with 31. 4% of patients reaching HiSCR75 at Week 16 versus 23.",
                "category": "company",
                "datetime": 1792700231,
                "headline": "AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial"
              },
              {
                "id": 143103164,
                "url": "https://finnhub.io/api/news?id=2dbc0d50c47ad5d9710fb4d159ed7199b44660af8e5dc5497c1789e229a38967",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal, a result RBC Capital called underwhelming.",
                "category": "company",
                "datetime": 1792689431,
                "headline": "MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”"
              },
              {
                "id": 143103165,
                "url": "https://finnhub.io/api/news?id=6c0d056ccf9f1135251280d1acd7927afb8a455303ac9dbe39ffec3b45a12040",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Avalo Therapeutics' (AVTX) abdakibart remains promising for hidradenitis suppurativa, with phase 2 r",
                "category": "company",
                "datetime": 1792687501,
                "headline": "Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says"
              },
              {
                "id": 143133242,
                "url": "https://finnhub.io/api/news?id=ab06dbcfc8c9fda6da870d24eef910ae8ad3a925ba64bde94b9b5906ee426790",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/22/MoonLake-Immunotherapeutics-NASDAQ-MLTX.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "MoonLake stock rallies after AbbVie HS data misses competitor benchmarks, reinforcing sonelokimab's competitive positioning ahead of 2027 launch plans.",
                "category": "company",
                "datetime": 1792679019,
                "headline": "What's Going On with MoonLake Immunotherapeutics Stock on Thursday?"
              },
              {
                "id": 143133243,
                "url": "https://finnhub.io/api/news?id=02df5dabbc1491d80c6f41322491c2fcf135f4085d2f420bcc2439c3682f945c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/22/Abbvie.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie reports Phase 3 INTREPID trial results for lutikizumab in treating moderate to severe cases of hidradenitis suppurativa.",
                "category": "company",
                "datetime": 1792678669,
                "headline": "AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst"
              },
              {
                "id": 143100073,
                "url": "https://finnhub.io/api/news?id=e60799b134e88ade40f53b8d8e31567a6b7a8c6ff71a1e315367df956edfa351",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "With AI stocks making waves, some prudent investors are looking at healthcare names to diversify amid concerns about an AI data center slowdown. AbbVie Inc. (NYSE:ABBV) ranks eighth on our list of the top 10 stocks Jim Cramer and billionaire Ken Fisher like. The stock has gained about 23% over the past year, but can […]",
                "category": "company",
                "datetime": 1792674129,
                "headline": "Jim Cramer and Ken Fisher Like This Healthcare Stock"
              },
              {
                "id": 143100067,
                "url": "https://finnhub.io/api/news?id=c961cd8dc79da3030f722b8571c7e6f417681b16b6825464c1ab44e73c037770",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals like Merck and AbbVie.",
                "category": "company",
                "datetime": 1792674029,
                "headline": "JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up"
              },
              {
                "id": 143100074,
                "url": "https://finnhub.io/api/news?id=e4b374b051f009885f91bc37c7288615235ff10b3d0cba575c273b8450b5a6ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint and 8 ranked secondary endpoints.",
                "category": "company",
                "datetime": 1792674000,
                "headline": "AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa"
              },
              {
                "id": 143099616,
                "url": "https://finnhub.io/api/news?id=e48ba4d3577200759641af302735cf47b8018d7c37d160d7c2a5ba52704e9210",
                "image": "https://www.chartmill.com/images/uploads/cannabis_theme_f843462963.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Cannabis stocks show narrow leadership: cap-weighted returns are positive while the average stock falls, led by profitable healthcare and consumer names.",
                "category": "company",
                "datetime": 1792672551,
                "headline": "Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Lifting"
              },
              {
                "id": 143100048,
                "url": "https://finnhub.io/api/news?id=2664af14cc6088897231f3cbc67e958e4f4b61005f9bf35b5bd4f94ad44457a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792672351,
                "headline": "Was There Any Sign Merck Stock Would Run?"
              },
              {
                "id": 143100075,
                "url": "https://finnhub.io/api/news?id=0256d33f2772215091f048d1cbd78eac61299f173ffcfa2e6c21eaddd5090bbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1792672203,
                "headline": "AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?"
              },
              {
                "id": 143100049,
                "url": "https://finnhub.io/api/news?id=f51f2cde69be65003b79d129e719322d83ca9adfc7e4b7bee4deb23441f0c884",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792671368,
                "headline": "Is Johnson & Johnson Stock Ready For A MedTech Stall?"
              },
              {
                "id": 143098610,
                "url": "https://finnhub.io/api/news?id=ea72c92ac42f266ee082dfa07d104cd41fa9a89e38b009bc33e6441ea29c0ba6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Three popular dividend stocks are paying out well above their free cash flow, and the gap between what each one earns and what it sends to shareholders reveals very different risks hiding behind familiar, trusted names.",
                "category": "company",
                "datetime": 1792668620,
                "headline": "These 3 Dividend Stocks Paid Out Over 90% of Free Cash Flow, but 1 Has Raised Its Dividend 54 Years in a Row"
              },
              {
                "id": 143101009,
                "url": "https://finnhub.io/api/news?id=8ca3b68dbd285b1154943454bfbf9016126008c20c982f7451ec7776d7727e8d",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1Lutikizumab met 8 ranked secondary endpoints,",
                "category": "company",
                "datetime": 1792660110,
                "headline": "AbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints"
              },
              {
                "id": 143071297,
                "url": "https://finnhub.io/api/news?id=52eab578ffc19c9e3ca9e4df5c44da8f98dac47174e2bd92e488e7e4291514cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792617521,
                "headline": "Are You Overpaying For Regeneron Stock Versus Its Rivals?"
              },
              {
                "id": 143071296,
                "url": "https://finnhub.io/api/news?id=ec3b7663a233787e4dd0e70783dd1fd4211f2d820ad3cb4d7e3f0f1664dbcd2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "REGENXBIO (NASDAQ:RGNX) outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or wet AMD, during a company event featuring retina specialists and executives. The company said it ex",
                "category": "company",
                "datetime": 1792616528,
                "headline": "REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy"
              },
              {
                "id": 143071295,
                "url": "https://finnhub.io/api/news?id=a0557876049c892b1e60e52e6bcc47345c2aa86dfc6f6c29d0ec47c25f582741",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The latest trading day saw AbbVie (ABBV) settling at $284.8, representing a -1.48% change from its previous close.",
                "category": "company",
                "datetime": 1792615504,
                "headline": "AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors"
              },
              {
                "id": 143071288,
                "url": "https://finnhub.io/api/news?id=60fab21e4459df56884c06727fb45337dcfb39de578b8bb76a818cb0b9a2c61f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792614371,
                "headline": "Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?"
              },
              {
                "id": 143070600,
                "url": "https://finnhub.io/api/news?id=41f5226f34db5af377548800478d88791c42319afe872a8b5c18c7788b798c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792602406,
                "headline": "What Changed In Amgen's Story?"
              },
              {
                "id": 143069992,
                "url": "https://finnhub.io/api/news?id=82130ba0110aa2fd1ced156ce32ad1c26e6b57e43137389ca90da1afdaac0f57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) and AstraZeneca PLC (NYSE:AZN) are both delivering earnings growth, but their latest results reveal different strengths. AbbVie is benefiting from rapid expansion in its immunology franchise, while AstraZeneca is generating considerable momentum from oncology and rare-disease treatments. According to Yahoo Finance’s latest available valuation snapshots, AbbVie trades at 16.39 times forward earnings, […]",
                "category": "company",
                "datetime": 1792595919,
                "headline": "AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story?"
              },
              {
                "id": 143067399,
                "url": "https://finnhub.io/api/news?id=41bdb83ce743416c2631fea3df110c559d75437fde7b419026dbcc70aa267750",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.",
                "category": "company",
                "datetime": 1792588802,
                "headline": "AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?"
              },
              {
                "id": 143062748,
                "url": "https://finnhub.io/api/news?id=2c53820768943970d54fa45488a6a6f1f7d8f974f2b5614eec6f77ad6147f010",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Social Security raises are locked to a government formula, but a growing number of retirees are routing their income strategy around it entirely, and the stocks they are buying span five very different industries.",
                "category": "company",
                "datetime": 1792584333,
                "headline": "Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead"
              },
              {
                "id": 143063698,
                "url": "https://finnhub.io/api/news?id=69c0c363bb71277d29dfbd23f080b767a0e3f5d2362a5cdf40606b2a584ab450",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and a global leader in aesthetics, will showcase the latest scientific evidence and clinical education supporting its expanding global aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) Dubai, taking place October 21-23, 2026.",
                "category": "company",
                "datetime": 1792584000,
                "headline": "Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence"
              },
              {
                "id": 143061711,
                "url": "https://finnhub.io/api/news?id=f8fcea11c063a0afd71845c816f48c6b31412dc9e77d6cbb50d0ae32a497562b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie is just one of several pharmaceutical companies to pen sponsorship deals in sport, blurring the commercial line between the two industries.",
                "category": "company",
                "datetime": 1792582834,
                "headline": "AbbVie races into F1 as pharma companies continue push into sport"
              },
              {
                "id": 143061712,
                "url": "https://finnhub.io/api/news?id=20443806c3227bceafb1e7d2c31cb7717d5c026d5f075cc268794c51ac7a358a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully been completed for ELAHERE® (mirvetuximab soravtansine for injection), and that a Letter of Intent (LOI) has been signed by both parties.",
                "category": "company",
                "datetime": 1792580460,
                "headline": "AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian Cancer"
              },
              {
                "id": 143099755,
                "url": "https://finnhub.io/api/news?id=72ec799b62eba6edcc9f3e7f04cc4da801cbd0327eecf4bb3f34e9267a270cee",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/21/Stock-Market-Trading-Chart-And-Analyzing.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Five sectors are higher and six are lower in Wednesday’s regular session, with cyclical sectors holding two of the top three positions alongside Technology. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.",
                "category": "company",
                "datetime": 1792580439,
                "headline": "Cyclicals Top Sectors In Wednesday Trading As Defensives Trail"
              },
              {
                "id": 143069332,
                "url": "https://finnhub.io/api/news?id=49714a605ad03653440bacb1e48a6895b113f9c5f411c274448ebfac5b8b2d7d",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Barclays  analyst Emily Field   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $325.",
                "category": "company",
                "datetime": 1792572567,
                "headline": "Barclays Maintains Overweight on AbbVie, Raises Price Target to $325"
              },
              {
                "id": 143069333,
                "url": "https://finnhub.io/api/news?id=723d8cc30e85ab6bb9b92f6a1d7152db65e3e7a2b6db34d4a73dac60c1149e62",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Ovarian cancer is the leading cause of death from gynecological cancers in Canada.1 In 2026, an estimated 3,000 individuals were diagnosed. Most are diagnosed at an advanced stage, and many eventually develop",
                "category": "company",
                "datetime": 1792566722,
                "headline": "Abbvie Signs ELAHERE Reimbursement LoI With The Pan-Canadian Pharmaceutical Alliance"
              },
              {
                "id": 143038856,
                "url": "https://finnhub.io/api/news?id=ec360a4c13d51252fc8575917923e9f0301ecea05f1edc0f73085e8b26ff8f30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Shares of Merck (MRK) returned 76.2% over the past year, compared with 17.4% for the S&P 500. U.S. growth for the company's cancer drug Keytruda is set to slow. Management said on the August 4 call that U.S. Keytruda growth will moderate as the drug reaches peak penetration across several key indications. Barron's also reported on October 7 that a Dutch court barred Merck from selling subcutaneous Keytruda in eight European markets. So how much of what Merck sells is Keytruda.",
                "category": "company",
                "datetime": 1792549234,
                "headline": "What Happens To Merck Stock If Keytruda Sales Stop Growing?"
              },
              {
                "id": 143032156,
                "url": "https://finnhub.io/api/news?id=e49558c555026b92434592fdc119c2a0057ebb415679b659eb4a3f1b8bd61926",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.",
                "category": "company",
                "datetime": 1792532102,
                "headline": "AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 143030200,
                "url": "https://finnhub.io/api/news?id=ab6926f343d508d471ec02b76b5ac95638fed34c8a5281849dcb3b3907f24457",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Spyre Therapeutics' (SYRE) combination therapy approach for inflammatory bowel disease gained furthe",
                "category": "company",
                "datetime": 1792514901,
                "headline": "Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says"
              },
              {
                "id": 143025748,
                "url": "https://finnhub.io/api/news?id=b1144ac6b8e565c5c7a907f3a3b8d92fea2e2a2393e20cd4027cfef710225a1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment.",
                "category": "company",
                "datetime": 1792501926,
                "headline": "Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher"
              },
              {
                "id": 143025749,
                "url": "https://finnhub.io/api/news?id=ca671eb2ec8a45d91dcd78aa900e009afb5d01c246d395ea435a96f98af2ad39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV), announced today that Health Canada has approved SKYRIZI® (risankizumab) for the treatment of pediatric patients aged 6 to <18 years of age with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.3 The approval expands treatment options for eligible children and adolescents living with this chronic inflammatory disease, which can affect much more than the skin.",
                "category": "company",
                "datetime": 1792497660,
                "headline": "Health Canada Approves SKYRIZI® (risankizumab) for Children Living with Moderate to Severe Plaque Psoriasis"
              },
              {
                "id": 143025747,
                "url": "https://finnhub.io/api/news?id=128de9dccf2e0ef9e95ed19a22820939a1dda8433b9743832bd85afc5b28a74a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team. At the center of the partnership is AbbVie Race to Innovate, a multi-year, purpose-driven campaign, built on a shared belief that innovation is never finished.",
                "category": "company",
                "datetime": 1792497300,
                "headline": "AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community"
              },
              {
                "id": 143022281,
                "url": "https://finnhub.io/api/news?id=50f9b627fa3ce0b22af7021f9aebc3e7da826c78555020e22b24b208e054663b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Two drugs, Mounjaro and Zepbound, accounted for $14.9 billion of Eli Lilly's (LLY) $23.0 billion in revenue during fiscal Q2 2026. This leaves Eli Lilly relying on two medicines for most of its sales at a time when the price it gets for them is falling. So why is so much of Eli Lilly's business running through two drugs.",
                "category": "company",
                "datetime": 1792494177,
                "headline": "Is Eli Lilly Stock Too Dependent On Two Drugs?"
              },
              {
                "id": 143026995,
                "url": "https://finnhub.io/api/news?id=6aaf2199a487293b74b6e89c45fe3f2f8bc6eb2bdda15a548f6b68a9c4363ca5",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team. At the center of",
                "category": "company",
                "datetime": 1792483074,
                "headline": "AbbVie Inks Multi-Year Collaboration With McLaren Racing To Be Its Official Pharmaceutical Partner Of McLaren Mastercard Formula 1 Team"
              },
              {
                "id": 143021726,
                "url": "https://finnhub.io/api/news?id=aa26742ea516d51ac213597b1c997816c7485dc59beb16639b23ac31407b96f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Key Stats for AbbVie StockCurrent Price: $282. 68Target Price (Mid): ~$367Street Target: ~$283Potential Total Return: ~30%Annualized IRR: ~6% / yearWhat Happened?AbbVie (ABBV) presented primary Phase 2a results for ABBV-466, its investigational two-drug Crohn’s disease combination, at a gastroenterology meeting in Barcelona on October 19.",
                "category": "company",
                "datetime": 1792468609,
                "headline": "AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial. Here’s What It Means for a Stock Up 24% in 2026"
              },
              {
                "id": 143020608,
                "url": "https://finnhub.io/api/news?id=5cc767b9143d7093cf8d07efb52939d79cc2dd4f555b5fa8a896fb2d81c14981",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193136073/image_2193136073.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "RIG portfolio review ranks 15 undervalued vs. 15 overvalued dividend stocks using 52-week highs/lows. Check out the list here.",
                "category": "company",
                "datetime": 1792458299,
                "headline": "15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now"
              },
              {
                "id": 143012144,
                "url": "https://finnhub.io/api/news?id=474d8c1a04257bccad1db173261e20deb67dc3db0abecc7bc43f02656bded33a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Two option-income ETFs sell calls against the same index, pay nearly identical yields, and yet one nearly doubled the other's total return over the past year. The way each fund is built explains why.",
                "category": "company",
                "datetime": 1792447417,
                "headline": "GPIX Out-Yielded JEPI and Returned 17.37% to Its 9.33%. JEPI Is Still 9.5 Times Bigger"
              },
              {
                "id": 143009434,
                "url": "https://finnhub.io/api/news?id=ccd3bfc42e17638bb8690e5cbd95b52c81e11850581647a7b913fc92d23da16d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "They may just be getting started.",
                "category": "company",
                "datetime": 1792431301,
                "headline": "2 High-Flying Dividend Stocks to Buy and Hold for a Decade"
              },
              {
                "id": 143009574,
                "url": "https://finnhub.io/api/news?id=8070bf91d38ecf0cb55fe6c532381fe54aad64d0db7dcf4b2a2b80d46cc14f93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.",
                "category": "company",
                "datetime": 1792430174,
                "headline": "How Much Upside Is Left In Regeneron Stock?"
              },
              {
                "id": 143008509,
                "url": "https://finnhub.io/api/news?id=50d1bc3a8e7cdf3b0ac1a17a125d300d6a61758bbaea06444f06dc022823753d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investors holding Gilead Sciences (GILD) likely bought into a steady profit engine. The company relies on HIV drugs, led by Biktarvy, to earn money year after year and fund a reliable dividend. Gilead spent the first half of 2026 acquiring other businesses, including Arcellx and Tubulis, before reporting its fiscal second quarter on August 4, 2026. What did those deals do to the profit you were counting on.",
                "category": "company",
                "datetime": 1792424621,
                "headline": "What Has Changed About Owning Gilead Stock?"
              },
              {
                "id": 143008516,
                "url": "https://finnhub.io/api/news?id=375b638b7eaf2da6bdc2c49f84cac71f9af6720efd645a54ef438ec519348a20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) reported new Phase 2a data for ABBV-466 in Crohn's disease at recent major medical meetings. The dual-targeting ABBV-466 therapy produced higher endoscopic remission rates than single-pathway treatments in the Phase 2a study. Management flagged multiple new and updated presentations on its solid tumor pipeline for the 2026 ESMO Congress. The ABBV-466 Crohn's data and upcoming oncology results only capture part of what investors may want to assess on AbbVie today. Take a...",
                "category": "company",
                "datetime": 1792422942,
                "headline": "AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts"
              },
              {
                "id": 143006662,
                "url": "https://finnhub.io/api/news?id=4018028322ba62a71c0bd20e61d8ff986a7942c1337ff3d1ede4676443c39533",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) are navigating a familiar pharmaceutical challenge, which revolves around replacing revenue from established medicines with newer products. Despite that broad similarity, investors are valuing their progress very differently. According to Yahoo Finance’s valuation data, AbbVie trades at 16.39 times forward earnings, compared with just 9.36 times for […]",
                "category": "company",
                "datetime": 1792417416,
                "headline": "AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying?"
              },
              {
                "id": 143006605,
                "url": "https://finnhub.io/api/news?id=d8336ff84d088f1fee01e07ce68f8bcfd97ec3f72a7cc63f58f1d6840e973601",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investors are paying a premium for Johnson & Johnson (JNJ) stock. It trades at 29.2 times earnings, compared to 22.9 for the S&P 500. Shareholders paying that premium need to understand exactly what they are buying, and the priorities at the company have changed. A year ago, during the fiscal Q3 2025 call, executives emphasized how the business would maintain growth despite the loss of exclusivity for STELARA, which is the point when rivals can sell copies of a drug. The corporate focus has shif",
                "category": "company",
                "datetime": 1792414556,
                "headline": "Has Johnson & Johnson Stock Become A Different Bet?"
              },
              {
                "id": 143006658,
                "url": "https://finnhub.io/api/news?id=128f392596d085f3a087a2d4ba623a478b80c0f19e3bbeaab0568482cbae6a3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.",
                "category": "company",
                "datetime": 1792411200,
                "headline": "AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results"
              },
              {
                "id": 143006652,
                "url": "https://finnhub.io/api/news?id=c79cc3ea8070060c0380f55e878aa5ab00c43a86a90f2ba8fe4299a8dbdd4c02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Palantir, BP, Palo Alto Networks, Visa and AbbVie are defying market gloom with strong share gains, earnings growth forecasts and distinct opportunities across key sectors.",
                "category": "company",
                "datetime": 1792411200,
                "headline": "Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie"
              },
              {
                "id": 143005743,
                "url": "https://finnhub.io/api/news?id=f5a6cd78c15e0515c9af271b1393a8bd926823a0d1d656706a815f9318c4b707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is what the numbers actually say about whether this healthcare giant earns its premium valuation.",
                "category": "company",
                "datetime": 1792408521,
                "headline": "Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead"
              },
              {
                "id": 143000058,
                "url": "https://finnhub.io/api/news?id=d06b65f833a91e459cf70b016be92fb549f147c666cf3a81ffd957e6c178d086",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remissiona at Week 12 than either monotherapy in patients with Crohn's disease (CD). The difference in endoscopic remissiona rates between ABBV-466 and monotherapy groups further increased at Week 24. The findings are from the TARGET-CD study, an ongoing open-label, treat-through, Phase 2a platform study in patients wit",
                "category": "company",
                "datetime": 1792396800,
                "headline": "AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease"
              },
              {
                "id": 143007604,
                "url": "https://finnhub.io/api/news?id=1fe5cdfc26d06891dbaee2c8a21b939ed5a5e54523d652c1c536b246cc1ba47e",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remissiona at Week 12 than either",
                "category": "company",
                "datetime": 1792382735,
                "headline": "AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease"
              },
              {
                "id": 143007605,
                "url": "https://finnhub.io/api/news?id=de58a95a089fcfb961ce00d82d0846745f7fbdd5d31a1cce474cb79196cae766",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "20 scientific presentations underscore the breadth of AbbVie&#39;s leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®",
                "category": "company",
                "datetime": 1792378877,
                "headline": "Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW"
              },
              {
                "id": 143007606,
                "url": "https://finnhub.io/api/news?id=4d995477e520f3dab2265e86d0ff402482a2d50bb9aee82d3847394c8885bc9e",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie&#39;s oncology portfolio to address diverse patient needs through next-generation",
                "category": "company",
                "datetime": 1792378285,
                "headline": "Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients"
              },
              {
                "id": 142991318,
                "url": "https://finnhub.io/api/news?id=09701ea5be45e810444839bc54903c67304650515cd36dc48d4d6fb281596c53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date.",
                "category": "company",
                "datetime": 1792361400,
                "headline": "/C O R R E C T I O N - AbbVie/"
              },
              {
                "id": 142989742,
                "url": "https://finnhub.io/api/news?id=f2cd887d4b1d18432eaa6d7d83f05ffd1b5e22b54f9992ad344506ef07bcc26b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date.",
                "category": "company",
                "datetime": 1792361400,
                "headline": "AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio"
              },
              {
                "id": 142960211,
                "url": "https://finnhub.io/api/news?id=3cd6b334dacd22b1da54c95de7946c5985810e696ccdc4478ddbe6dac4398fb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee deal and lingering debt load could mean for the payout's future.",
                "category": "company",
                "datetime": 1792238420,
                "headline": "AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?"
              },
              {
                "id": 142959568,
                "url": "https://finnhub.io/api/news?id=401568fc9367f5556f1946b8e1b6a1b16d2208b0d4956c944ac06bcd0423ffe1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Rising rates can expose dividend traps, but this Dividend King is built to keep paying.",
                "category": "company",
                "datetime": 1792227840,
                "headline": "Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle"
              },
              {
                "id": 142959151,
                "url": "https://finnhub.io/api/news?id=a5d1ccb829c61555eb687e44f3e40dfe017955f6626e8083e4c0ef88880252be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.",
                "category": "company",
                "datetime": 1792216800,
                "headline": "SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026"
              },
              {
                "id": 142958780,
                "url": "https://finnhub.io/api/news?id=65bd49ddd054c41c8d5bddd4298930d57f987a6ad9942791b8227ed2353e3318",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie and Genmab reported that epcoritamab plus R-CHOP achieved statistically significant Phase 3 progression-free survival results in newly diagnosed high-risk DLBCL, with safety in line with the known profiles of the component therapies. The epcoritamab outcome adds another late-stage oncology asset alongside AbbVie’s expanding immunology portfolio and reinforces how clinical execution is reshaping its mix beyond legacy therapies like Humira and Imbruvica. Next, the focus shifts to how...",
                "category": "company",
                "datetime": 1792214171,
                "headline": "What AbbVie (ABBV)'s Phase 3 Lymphoma Win Means For Shareholders"
              },
              {
                "id": 142957851,
                "url": "https://finnhub.io/api/news?id=7fbbc87921f5eb6aebe1a84de39e7ad8c2e918ec67c718d7d159b99c51415cdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the identical period would have yielded about $11,790. By mid-2026, two drugs, Zepbound and Mounjaro, accounted for most of the company's sales. How early did those two drugs show up in what Lilly said and filed.",
                "category": "company",
                "datetime": 1792205822,
                "headline": "What Was Eli Lilly Telling You Before Its Stock Ran?"
              },
              {
                "id": 142955409,
                "url": "https://finnhub.io/api/news?id=ddb56e3c9661675f49062aebfa86d5d29be9a5e9841df1481875ad51a4717ce5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9% return of the S&P 500. A higher forecast or a climbing share price means little in isolation. When the corporate numbers and the technical chart align, however, the combination warrants closer scrutiny. So how far did management raise its forecast, and why.",
                "category": "company",
                "datetime": 1792198389,
                "headline": "When Amgen's Forecast And Chart Say The Same Thing, Pay Attention"
              },
              {
                "id": 142954216,
                "url": "https://finnhub.io/api/news?id=4ceb14cf168e6a03b7c306392042043ca662a3e864ad75e2c2967d3eb042758f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal 2025 revenue. Yet another segment of the HIV business is growing at a much faster pace, and it targets people who do not currently carry the virus. Gilead expects a regulatory decision regarding a new option in this category in early 2027. So what is that business, and how much is it selling today.",
                "category": "company",
                "datetime": 1792197478,
                "headline": "Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?"
              },
              {
                "id": 142953213,
                "url": "https://finnhub.io/api/news?id=e0d5644bdb1a894b876cd8a527913e2c730f1125e7d0685ae819033f70376096",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 500. As the broader market rises and falls each day, the pharmaceutical stock's individual performance blends with the rest of that capital. So when the market drops, does Amgen make your losses bigger.",
                "category": "company",
                "datetime": 1792196033,
                "headline": "Is Amgen Stock Increasing Your Market Risk?"
              },
              {
                "id": 142950770,
                "url": "https://finnhub.io/api/news?id=05c78a41cc2ccbc2a2cc73d7aa3eb79ef51dfdb81223cb04b0ceaa6a9ff2e35f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "You'd need to invest over $200,000 in the pharma leader at its current price.",
                "category": "company",
                "datetime": 1792187299,
                "headline": "Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends"
              },
              {
                "id": 142950071,
                "url": "https://finnhub.io/api/news?id=3833189a2fa52e423ed054c08fbe5c05a4783defd1c2f79b9759265d4d921569",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Key TakeawaysAbbVie lowered its 2026 adjusted EPS guidance to $13. 76 to $13.",
                "category": "company",
                "datetime": 1792175075,
                "headline": "AbbVie or Altria: The One Dividend Stock I’d Hold for the Next 10 Years"
              },
              {
                "id": 142949116,
                "url": "https://finnhub.io/api/news?id=3ef7e3394222e814a77c1b38975d9ebbbf55e72abf7cf7332ad721955ff8675c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth in important parts of their pharmaceutical portfolios. According to Yahoo Finance’s September 23, 2026 valuation snapshot, Pfizer trades at 9.67 times forward earnings, compared with AbbVie’s 16.39 times. That makes Pfizer cheaper on a forward P/E basis, but […]",
                "category": "company",
                "datetime": 1792172610,
                "headline": "Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?"
              },
              {
                "id": 142949117,
                "url": "https://finnhub.io/api/news?id=7c834a7f66d845c3fd5471a2eb3bd0c515377886450be67a9025294c95c874a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) have something important in common that is important for investors, which is that both must demonstrate that newer medicines can sustain earnings as their established blockbusters face competition. However, the companies are at different stages of that transition, creating an interesting valuation dilemma. According to Yahoo […]",
                "category": "company",
                "datetime": 1792172175,
                "headline": "AbbVie vs. Merck: Which Pharma Stock Offers Better Value?"
              },
              {
                "id": 142947985,
                "url": "https://finnhub.io/api/news?id=4b07b7f4174da3fe62a24f778a4ee3cbd750083e39e42570bb82c67c6f5cbbb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) is delivering strong returns this year, with shares surging by over 23% year-to-date. In comparison, the broader market has returned nearly 13% in the same period. Yahoo Finance’s latest data puts AbbVie’s forward P/E at 16.39x, which is considerably different from the company’s trailing P/E of 74.88 because AbbVie’s reported earnings have […]",
                "category": "company",
                "datetime": 1792164779,
                "headline": "AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?"
              },
              {
                "id": 142949113,
                "url": "https://finnhub.io/api/news?id=1e0741edf65091d0e42169e70128df867d04f27391a6c9aa9797ec219e0b531b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Forget the AI stocks. These five stocks have momentum right now.",
                "category": "company",
                "datetime": 1792162620,
                "headline": "5 Stock Ideas for Your Short List"
              },
              {
                "id": 142948754,
                "url": "https://finnhub.io/api/news?id=a5223494ee980451496ea32dd15ff80034030f7a5281ce0552d36a92620e1934",
                "image": "https://image.cnbcfm.com/api/v1/image/108420663-17921701471792170144-49040390703-1080pnbcnews.jpg?v=1792170146&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "Kevin Simpson, founder and CEO of Capital Wealth Planning, joins CNBC's 'Halftime Report' to detail his latest portfolio move. The Investment Committee shares their top healthcare plays.",
                "category": "company",
                "datetime": 1792156269,
                "headline": "Trade Tracker: Kevin Simpson buys AbbVie"
              },
              {
                "id": 142922981,
                "url": "https://finnhub.io/api/news?id=59002fc40427ce20c00702f641fd3faf90089b2eadde96cec9c2aea238c2a5c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie has delivered strong share price gains in recent years, and the latest drug updates keep the story in the spotlight. The key issue for anyone looking at the stock today is whether that rally is still grounded in the cash it can generate. With the Discounted Cash Flow (DCF) lens in focus, the question is how the current price lines up with the stream of cash flows investors expect AbbVie to produce over time. AbbVie has returned 211.2% over the past 5 years, which puts real weight on...",
                "category": "company",
                "datetime": 1792106493,
                "headline": "AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands"
              },
              {
                "id": 142922982,
                "url": "https://finnhub.io/api/news?id=d961c14879beee43810514e472ac93ef03bf4d055e854f3218bb2c812b7ddea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The EPCORE DLBCL-2 study showed a statistically significant reduction in the risk of disease progression or death versus R-CHOP alone. Trial data point to clinically meaningful efficacy in a first line setting for high risk diffuse large B cell lymphoma patients. Epcoritamab plus R-CHOP is only one piece of the story for AbbVie as the oncology pipeline...",
                "category": "company",
                "datetime": 1792102608,
                "headline": "What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?"
              },
              {
                "id": 142922285,
                "url": "https://finnhub.io/api/news?id=e55ca2d20a0f963b7d205e3befbf4d17eb09a9b24af869bcc4bfcaa8989ea739",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie, meanwhile, closed just shy of a record high, with shares ticking up 0.6% to $283.40.",
                "category": "company",
                "datetime": 1792096200,
                "headline": "Gilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear."
              },
              {
                "id": 142922269,
                "url": "https://finnhub.io/api/news?id=c7865f7724923f82ec5f2ffee87e7389c60a2dc5ec98a0c9ffd0eb37e2d969ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand exactly what they hold, and the drugmaker's priorities have changed. During the fiscal Q4 2024 call in February 2025, executives noted that conditions for the GARDASIL vaccine in China remained challenging. By the August 4, 2026 call, management emphasized something else. So what does management talk up now.",
                "category": "company",
                "datetime": 1792093589,
                "headline": "How Has Merck's Story Changed?"
              },
              {
                "id": 142921398,
                "url": "https://finnhub.io/api/news?id=2b18ce41a3e94510025480876d20ce49fe7f7188ad0a0878059123a71d06e9ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The IPO market may be in a bit of a slump as investors wait for Anthropic to finally file officially for a stock sale.",
                "category": "company",
                "datetime": 1792085931,
                "headline": "Cathie Wood-Backed Biotech IPO Pops in Debut"
              },
              {
                "id": 142922286,
                "url": "https://finnhub.io/api/news?id=c9ab4fd2e843b48f89cd1b73245dbdd106bd8d0e96e47d3e46cccda7bf0ec353",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Biopharma giant AbbVie is set to report its Q3 results on Oct. 30.",
                "category": "company",
                "datetime": 1792077749,
                "headline": "AbbVie’s Q3 2026 Earnings: What to Expect"
              },
              {
                "id": 142919291,
                "url": "https://finnhub.io/api/news?id=9b4dc5f84549fc23cc11e827e82d6faa97d78cdf14ce8f97fa48caaeb3957450",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.",
                "category": "company",
                "datetime": 1792074965,
                "headline": "AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142915328,
                "url": "https://finnhub.io/api/news?id=b3a8c83dcbe2957ee2b7ef5bda75d1c593820e341cd92a0184bdff2f60f5c80b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors paying that premium appear to be counting on more growth. The company raised its 2026 guidance on October 13, and Chief Executive Joaquin Duato pointed to one new product as one of its most transformative MedTech innovations. So which product is it.",
                "category": "company",
                "datetime": 1792069769,
                "headline": "Where Could Johnson & Johnson's Next Growth Come From?"
              },
              {
                "id": 142904852,
                "url": "https://finnhub.io/api/news?id=2207e6c4cebd8214810f97bad4d72147d15d8cfb1d750d8531729e492dec4984",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_20_d1d9e6697d.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Hotter September inflation revived Fed hike bets and a Gartner warning crushed AI neoclouds. Pharma caught a bid, BlackRock hit a record, BofA got fined.",
                "category": "company",
                "datetime": 1792050932,
                "headline": "Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq"
              },
              {
                "id": 142902342,
                "url": "https://finnhub.io/api/news?id=9d68f92c16833503339ea5d5df75459423360a1508a93c70603f4b8b209e8fdf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly (LLY:NYSE) stock rose roughly 4% on Wednesday, October 14, joining a broad rally in healthcare stocks. No major Lilly news drove it.",
                "category": "company",
                "datetime": 1792029766,
                "headline": "Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day"
              },
              {
                "id": 142889244,
                "url": "https://finnhub.io/api/news?id=434733031d20fe4cdc19bc79cf48d12b65f1d04ad018b78d4055f1173b8c98bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying down a balance owed to its partner Sanofi. This obligation reduced the revenue Regeneron reported from the partnership. So what does Regeneron gain now that the balance is paid off.",
                "category": "company",
                "datetime": 1792014348,
                "headline": "What Could Send Regeneron Stock Higher?"
              },
              {
                "id": 142887222,
                "url": "https://finnhub.io/api/news?id=0b7c292179b56ca652306005b9567d0a0523eab678139849606472987ea2e20f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1792004701,
                "headline": "Top S&P500 movers in Wednesday's session"
              },
              {
                "id": 142887437,
                "url": "https://finnhub.io/api/news?id=19b85bc72b748e5c4f9df4d280603355fd2cbda4b56f2bfe016353e892bc2ed5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Shares of Lilly, the world’s largest pharmaceutical company by market value, rallied above their 50-day moving average to mark their best level since August.",
                "category": "company",
                "datetime": 1791999180,
                "headline": "Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today."
              },
              {
                "id": 142920041,
                "url": "https://finnhub.io/api/news?id=7b096a03ff0e5a5a24de8845d2b27a90a2faf3a7e3424ee1fbb60f2ba53646b1",
                "image": "https://image.cnbcfm.com/api/v1/image/108410613-17920113481792011345-49001508413-1080pnbcnews.jpg?v=1792011347&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1791998129,
                "headline": "Take profit in healthcare strength across the board, says Mizuho's Jared Holz"
              },
              {
                "id": 142885916,
                "url": "https://finnhub.io/api/news?id=b622cb959cbffaf6a3f606c989db14bb104d90fd68454f6db70586c3daa7cf5d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1791995703,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 142886457,
                "url": "https://finnhub.io/api/news?id=495209183eea6d7318d1d4db2134daf72888cf50b52194a8d8bf4877687ca229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.",
                "category": "company",
                "datetime": 1791990540,
                "headline": "Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?"
              },
              {
                "id": 142882647,
                "url": "https://finnhub.io/api/news?id=0d08b98bbe208e93a6ba98aaa26416224fdc4a7a25aa08d9b69e012ea8bf81a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Earlier this week, AbbVie reported Phase 3 AFFIRM data showing subcutaneous SKYRIZI induced endoscopic remission and ulcer-free endoscopy in a meaningful share of adults with moderately to severely active Crohn’s disease, with safety consistent with its existing profile. The findings, presented at the 2026 American College of Gastroenterology meeting, could support regulatory reviews of a more convenient subcutaneous induction option and deepen AbbVie’s presence in difficult-to-treat...",
                "category": "company",
                "datetime": 1791983395,
                "headline": "Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?"
              },
              {
                "id": 142882629,
                "url": "https://finnhub.io/api/news?id=e7ee454d06681d6eed59a914146d59e967214b8f3d686043bbcc75da682651e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The lineup includes ICOTYDE, an oral treatment for plaque psoriasis. The company has yet to disclose sales figures for the medication. How much the drug can ultimately add to J&J remains an open question. Anyone purchasing shares today takes on that unknown before the answer is in.",
                "category": "company",
                "datetime": 1791980295,
                "headline": "The Open Question Under Johnson & Johnson Stock's Price"
              },
              {
                "id": 142882649,
                "url": "https://finnhub.io/api/news?id=936c9e61fdf5e334f11234d083077790e7ed5779d18c5134613a1b59489323f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than you expect.",
                "category": "company",
                "datetime": 1791980116,
                "headline": "Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins?"
              },
              {
                "id": 142882630,
                "url": "https://finnhub.io/api/news?id=5e4289c0c9b96dfa1e95a00694f6be0915f8672c2b831308bed3a3fce09f0551",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.",
                "category": "company",
                "datetime": 1791979740,
                "headline": "Bet on These Healthcare ETFs to Benefit From the Aging US Population"
              },
              {
                "id": 142882651,
                "url": "https://finnhub.io/api/news?id=0fb26294ad174136a8ced8aadd5f8c5d1823f3a9b2995fc1562822b3ebbacb22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1791979202,
                "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 142915760,
                "url": "https://finnhub.io/api/news?id=96ad35f5ef177e04917a658689de84478274bbf6edf6e6f298c9a08636fefbf6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Nasdaq-100-way-down.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.",
                "category": "company",
                "datetime": 1791977994,
                "headline": "Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today"
              },
              {
                "id": 142881695,
                "url": "https://finnhub.io/api/news?id=7fea1d49ce468ac5cda1986cdec52c42bb30275066096747e2bcadca75f062b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something bigger, and the math behind their payouts tells the story.",
                "category": "company",
                "datetime": 1791976502,
                "headline": "Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying"
              },
              {
                "id": 142915769,
                "url": "https://finnhub.io/api/news?id=2b743e7a2c154c563c192ced156b0a277e5f5114d04f6476217f58acbd737cb7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Stock-Market-Trading-Chart-And-Analyzing.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Three sectors are higher and eight are lower in Wednesday&#39;s regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with no single sector pulling away from the group.",
                "category": "company",
                "datetime": 1791976493,
                "headline": "8 Of 11 Sectors Fall Wednesday As Defensives Lead"
              },
              {
                "id": 142874927,
                "url": "https://finnhub.io/api/news?id=b31d5f876dd2b345fc8bfd8f04e7e86047f12335e584c5f43db877a31e6b39f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.",
                "category": "company",
                "datetime": 1791968807,
                "headline": "1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off"
              },
              {
                "id": 142856069,
                "url": "https://finnhub.io/api/news?id=19ddbf443d05e538002ed8fb8a4b92ac9ed26efb14a4416a1787066e2d586672",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what",
                "category": "company",
                "datetime": 1791935331,
                "headline": "Is Amgen Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142854429,
                "url": "https://finnhub.io/api/news?id=af9e77fe534e9c773a98bc5f9ac2097c3584d64f99fcc24c59aaa3f3cf1b0f29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "One faces patent cliffs and revenue concentration; the other dominates a booming market but trades at a premium valuation.",
                "category": "company",
                "datetime": 1791927721,
                "headline": "AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142854423,
                "url": "https://finnhub.io/api/news?id=5bc081dc70d815ffa88823067c5acd0248f42961683e09e9d61876123ee214f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market exclusivity. Both drugmakers point to 2028 as the year that matters. Pfizer is acquiring drugs and cutting costs to bridge the gap, while Bristol Myers still relies on Eliquis, an older drug that continues to grow. So what did each company tell investors at its latest report about how that replacement is going.",
                "category": "company",
                "datetime": 1791921571,
                "headline": "What Does Bristol-Myers Squibb Offer That Pfizer Does Not?"
              },
              {
                "id": 142853444,
                "url": "https://finnhub.io/api/news?id=d3c9a96d4f639435dd81c82294ec2c31c03002bcc1a4f295b7f7efba4bcca128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. Justifying that multiple may require sustained growth, yet most of Lilly's sales still come from the company's two dominant blockbusters, Zepbound and Mounjaro. The pharmaceutical maker has a newer drug on sale and expects to launch it in all major markets worldwide in 2027. So what is the new drug, and is it selling.",
                "category": "company",
                "datetime": 1791919463,
                "headline": "What Is Eli Lilly Stock's Biggest Opportunity?"
              },
              {
                "id": 142853469,
                "url": "https://finnhub.io/api/news?id=17315436ec22d5a811395fd8655a2d3735059c31515c98796592074305f8f374",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie today announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with SKYRIZI® (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease (CD). Presented at the American College of Gastroenterology 2026 Annual Scientific Meeting, the findings build on the previously reported efficacy results of subcutaneous (SC) SKYRIZI® treatment, showing new endoscopic remissionii and ulcer-free endoscopyiii outcomes for patients receiving",
                "category": "company",
                "datetime": 1791918900,
                "headline": "AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease"
              },
              {
                "id": 142852452,
                "url": "https://finnhub.io/api/news?id=eaf0f620d711f1b94d3c99af4dfbfe394501fa1b7dc5277aae36da182e79f204",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by comparison.",
                "category": "company",
                "datetime": 1791909901,
                "headline": "5 High-Yield Dividend Stocks That Could Turn October’s Market Weakness Into Income"
              },
              {
                "id": 142852424,
                "url": "https://finnhub.io/api/news?id=cb66b2c5d945543b219e2f4be3f72ae91e15a16b4ab67d9a5af4fe11d5f8fdcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.",
                "category": "company",
                "datetime": 1791909014,
                "headline": "Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests"
              },
              {
                "id": 142884835,
                "url": "https://finnhub.io/api/news?id=930e582a1adbb6085a071d163150ab250381e1501d137c1faff64734668d44e9",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie today announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with SKYRIZI® (risankizumab-rzaa) in adults with moderately to severely active Crohn&#39;s disease (CD).",
                "category": "company",
                "datetime": 1791904830,
                "headline": "AbbVie Announces Data From Its Phase 3 AFFIRM Study Of SKYRIZI Demonstrates 35.8% Of Patients With Crohn's Disease Achieved Endoscopic Remission After Treatment"
              },
              {
                "id": 142884681,
                "url": "https://finnhub.io/api/news?id=c3445c40587dd6f68368df4f8cd794b9e2d33d42f3d409bcf38f5895a1b48554",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Merger-And-Acquisition-Business-Corporat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Alaunos Therapeutics acquired Velaris and raised $350 million to advance clinical therapies for pulmonary arterial hypertension through 2029.",
                "category": "company",
                "datetime": 1791897609,
                "headline": "Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?"
              },
              {
                "id": 142848693,
                "url": "https://finnhub.io/api/news?id=7080d2487b8b3fdcccce025d594bca2057f3180dcc75b63ffdae05b01fe4c4a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.",
                "category": "company",
                "datetime": 1791890940,
                "headline": "Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?"
              },
              {
                "id": 142850826,
                "url": "https://finnhub.io/api/news?id=b28ee841bb547fcc26557c569a6277ea410bc5cb494ceea2f398caae2601e85a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Four sectors are higher and seven are lower in Tuesday’s regular session, with cyclical sectors holding two of the top three positions. Materials sits well clear of the lower group, separated by a margin several times wider than any other gap in the table.",
                "category": "company",
                "datetime": 1791889260,
                "headline": "Cyclicals Lead Sectors In Tuesday Trading As Health Care Trails"
              },
              {
                "id": 142850009,
                "url": "https://finnhub.io/api/news?id=e6cef58304c69a5108eca20e3d738aad0386a9b97db84d56a99180749ac3aa86",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "RBC Capital  analyst Trung Huynh   reiterates AbbVie (NYSE:ABBV) with a Outperform and maintains $280 price target.",
                "category": "company",
                "datetime": 1791886841,
                "headline": "RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target"
              },
              {
                "id": 142850010,
                "url": "https://finnhub.io/api/news?id=3b7793eabc8c0371b36650af6d33e14320c4e81a5861a4c366f199ab36b3e34e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Netflix-Logo-On-A-Building-Exterior-With.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "CNBC traders picked Netflix, AbbVie and DocuSign, citing analyst support, strong momentum, breakthrough designations and a 10% FCF yield.",
                "category": "company",
                "datetime": 1791876538,
                "headline": "Netflix, DocuSign And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 142838670,
                "url": "https://finnhub.io/api/news?id=ffd2509bd6926f9dd68485996270e5389f6d0109aa4de6e784055f7183a7e4c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "How AbbVie’s latest data releases are reshaping the story AbbVie (ABBV) has packed the early October news cycle with fresh clinical data and regulatory milestones, spotlighting its immunology, oncology and metabolic franchises just weeks before its next earnings update. Investors are watching four developments in particular: Phase 3 readouts for SKYRIZI and RINVOQ in Crohn’s disease, new FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer, early obesity data for...",
                "category": "company",
                "datetime": 1791875883,
                "headline": "AbbVie (ABBV) Could Be 44% Below Fair Value On Fresh Pipeline Wins"
              },
              {
                "id": 142825453,
                "url": "https://finnhub.io/api/news?id=5c26291ca92708763cb3875dc9ab591493dcebb54023a277eefc0cab5d20c7fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.",
                "category": "company",
                "datetime": 1791849061,
                "headline": "AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142824540,
                "url": "https://finnhub.io/api/news?id=283d425ca2782e14d104ef0293015249cb37a8cbb0aae318bdb1820086755c7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) reached $281.04 at the closing of the latest trading day, reflecting a +1.65% change compared to its last close.",
                "category": "company",
                "datetime": 1791837906,
                "headline": "AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts"
              },
              {
                "id": 142822711,
                "url": "https://finnhub.io/api/news?id=4c955df73a5870ac01a4bfb542467101453f7ed4a3e4ac340997fd39304a05af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.",
                "category": "company",
                "datetime": 1791822002,
                "headline": "Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142821607,
                "url": "https://finnhub.io/api/news?id=ec6b899d8677cc971c4128635ebd24145e6368a585d1c01f876ab504597c907a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the immunology market.",
                "category": "company",
                "datetime": 1791814620,
                "headline": "Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?"
              },
              {
                "id": 142852057,
                "url": "https://finnhub.io/api/news?id=5cdcc57b88459383195882250c7b979168134becfc71ef3cf104c9671ec7e723",
                "image": "https://image.cnbcfm.com/api/v1/image/108399173-17918250391791825037-48956096490-1080pnbcnews.jpg?v=1791825038&w=1920&h=1080",
                "source": "CNBC",
                "related": "ABBV",
                "summary": "The Investment Committee gives you their top stocks to watch for the second half.",
                "category": "company",
                "datetime": 1791811308,
                "headline": "Final Trades: Netflix, AbbVie and Docusign"
              },
              {
                "id": 142819092,
                "url": "https://finnhub.io/api/news?id=01dff681fb097544aea2c0c9b86433efdb69ea47efd735d0cf701250b550a029",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall Street divided between a $297 bull case and a $246 bear case.",
                "category": "company",
                "datetime": 1791803709,
                "headline": "Prediction: AbbVie’s Next Billion-Dollar Opportunity Is Taking Shape"
              },
              {
                "id": 142819108,
                "url": "https://finnhub.io/api/news?id=6604f99421e23532e5a5850e2123a4af7ebb3e36d79acf162b43bce529295078",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomparvovec (sura-vec, ABBV-RGX-314) clinical program in wet age-related macular degeneration (wet AMD) ahead of the topline pivotal data anticipated in the fourth quarter of 2026. The event will be held in-person in New York, NY and available via webcast.",
                "category": "company",
                "datetime": 1791803100,
                "headline": "REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20"
              },
              {
                "id": 142820271,
                "url": "https://finnhub.io/api/news?id=213e05c796eecd995aa09459c797dcb92c9c70c22bc57db5945854c422f41af1",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn&#39;s disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroupsNew",
                "category": "company",
                "datetime": 1791774229,
                "headline": "Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s"
              },
              {
                "id": 142810093,
                "url": "https://finnhub.io/api/news?id=98c661ed0ff45874a7168ff5b1c6dc60fcb3a928f3e7f81d04a689c19ab0abc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.",
                "category": "company",
                "datetime": 1791768132,
                "headline": "SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH"
              },
              {
                "id": 142807097,
                "url": "https://finnhub.io/api/news?id=4d40487850fb8d85fc5a9177b3bcd59eda072ffb6c305e7184f052ddd4527cef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9-14. Data presented will include newly unveiled AFFIRM results showing efficacy for SKYRIZI® (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, open-label extension analyses demonstrating long-term outcomes with SKYRIZI in diffi",
                "category": "company",
                "datetime": 1791738000,
                "headline": "New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease"
              },
              {
                "id": 142807098,
                "url": "https://finnhub.io/api/news?id=b5477af582e703213b9d7e38c403cb77159443130daf402eac041f3c05debced",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, and not every high-yielder clears it. These five names span telecom, real estate, consumer staples, utilities, and pharma, and safety comes before yield in every case.",
                "category": "company",
                "datetime": 1791734444,
                "headline": "5 Dividend Stocks for Retirees Who Want More Than Just a Big Yield"
              },
              {
                "id": 142806923,
                "url": "https://finnhub.io/api/news?id=0e1f88e32d684ef29a5ec2cd4b8e528f14b92837c8da37909f2d611a40cee4d4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2199578213/image_2199578213.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "JPMorgan, Goldman Sachs and other big banks launch earnings season. CPI hits as yields hit two-decade highs. Trump announces an energy ceasefire between Russia and Ukraine.",
                "category": "company",
                "datetime": 1791725340,
                "headline": "Wall Street Brunch: Start Your Earnings Engines"
              },
              {
                "id": 142802643,
                "url": "https://finnhub.io/api/news?id=8eb2871796eddfe5f570c97290281c56a93b5046ccea1995ca399dfa5b2daf53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A super-high yield isn't everything.",
                "category": "company",
                "datetime": 1791709440,
                "headline": "AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway."
              },
              {
                "id": 142797825,
                "url": "https://finnhub.io/api/news?id=d0e4c844dfa87ed4f53dd4d26660626a03de6fc78fae246c12d12553264f870b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.",
                "category": "company",
                "datetime": 1791686100,
                "headline": "How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?"
              },
              {
                "id": 142792567,
                "url": "https://finnhub.io/api/news?id=11a786498782afaccf0262d5570d06ee18a18ddd114c981cf9f7594cc7351290",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Preview next week’s market-moving events—CPI, retail sales, Fed talk, and big bank earnings (JPM, GS, C, MS).",
                "category": "company",
                "datetime": 1791630000,
                "headline": "Banking Bellwethers Kick Off Earnings, Fed Chair's Speech In Focus"
              },
              {
                "id": 142781773,
                "url": "https://finnhub.io/api/news?id=0314de4f307d014e1b059754bc12bdca5f4e1c709e1220dd2844e54000f68bd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) received two FDA Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan in colorectal and non small cell lung cancer. The designations apply to biomarker defined patient groups in colorectal and non small cell lung cancer, two large solid tumor indications. The FDA decision marks the first Breakthrough Therapy status for telisotuzumab adizutecan, increasing attention on AbbVie’s antibody drug conjugate pipeline. The dual Breakthrough...",
                "category": "company",
                "datetime": 1791616313,
                "headline": "What Does AbbVie (ABBV) Winning Two FDA Breakthrough Tags Mean For Its Oncology Pipeline?"
              },
              {
                "id": 142791541,
                "url": "https://finnhub.io/api/news?id=2e3fc18273d0313408985b49d17e646e670649022a16be256bd517845bce243e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/10/Flags-Of-China-And-Usa-Painted-On-Cracke.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "John Moolenaar asks the US Defense Department to add 58 Chinese schools and 62 technology labs to its research funding restrictions list.",
                "category": "company",
                "datetime": 1791597257,
                "headline": "John Moolenaar Urges Defense Department to Add 120 Chinese Schools and Tech Labs to US Research Funding Watchlist"
              },
              {
                "id": 142772223,
                "url": "https://finnhub.io/api/news?id=d7341b07311e0a7aadb936df0d126442fa321eed83f51e517867f131ac1fb044",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.",
                "category": "company",
                "datetime": 1791593224,
                "headline": "Why Is Everyone Ignoring Gilead Stock's High Cash Yield?"
              },
              {
                "id": 142774378,
                "url": "https://finnhub.io/api/news?id=6ecf61a08d4e89e309d2bc77c13f5e7c620f7c06baba3507c179f7718a35d78e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Get a weekly dividend recap for Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates.",
                "category": "company",
                "datetime": 1791584761,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week October 11"
              },
              {
                "id": 142766263,
                "url": "https://finnhub.io/api/news?id=8ec035baab86cf7792f8c473ed9d920f88a6b869215a9474bf070dbaea0125ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a year of drug approvals and clinical trial results, arriving just as the company prepares for the patent loss on Keytruda, its top-selling drug. So what did Merck show investors over those twelve months.",
                "category": "company",
                "datetime": 1791569538,
                "headline": "Does The Move In Merck Stock Change Anything?"
              },
              {
                "id": 142792023,
                "url": "https://finnhub.io/api/news?id=9a92b71644171d20646a52ed44965c3d73e78a9bdef706023c48ec9b1e685fcd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 8.13% on an annualized basis producing an average annual return of 20.55%. Currently, AbbVie has a market capitalization of $481.85 billion.",
                "category": "company",
                "datetime": 1791562520,
                "headline": "Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years"
              },
              {
                "id": 142763972,
                "url": "https://finnhub.io/api/news?id=6fdf316f2d5ebe8c061465fe438ca485dfe8aabf63f03dc5c9d92f0f44f43b9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "These companies might bend during a downturn, but they won’t break.",
                "category": "company",
                "datetime": 1791557402,
                "headline": "A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens"
              },
              {
                "id": 142763840,
                "url": "https://finnhub.io/api/news?id=1d6ce00c721ad1924f83cd4763ba8a3c72a5f8b8e821088d4602014b0a5ec596",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Three of these six income stocks beat current Treasury bill yields, but a higher number on the label does not settle the argument once taxes, reinvestment risk, and dividend safety enter the picture.",
                "category": "company",
                "datetime": 1791555353,
                "headline": "Treasury Bills or Dividend Stocks? The Retirement Income Math May Surprise You"
              },
              {
                "id": 142764050,
                "url": "https://finnhub.io/api/news?id=6241482d4670bb6f2d789158b7ebcd3d68f4b48589cd9e9642a3ae4bc086e46c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.",
                "category": "company",
                "datetime": 1791554580,
                "headline": "Cancer Stocks to Consider as Oncology Innovation Accelerates"
              },
              {
                "id": 142761598,
                "url": "https://finnhub.io/api/news?id=aabf954f38432e37912390298b903621b43349d000a25b427d0e6de1ad0f4710",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Humira, the drug that built AbbVie (NYSE:ABBV), sold $756 million last quarter, down 35.9%. And yet total revenue still climbed 10.2% to $16.99 billion. That’s what replacing a blockbuster looks like when the replacements actually show up. AbbVie sells immunology medicines for conditions like psoriasis, Crohn’s disease, and rheumatoid arthritis, along with neuroscience drugs, cancer […]",
                "category": "company",
                "datetime": 1791552827,
                "headline": "AbbVie (ABBV) Outgrew Humira’s Collapse. Is its Forward P/E Fair for What Comes Next?"
              },
              {
                "id": 142761581,
                "url": "https://finnhub.io/api/news?id=dac28b3748f2eb337bdde00dc47ba0bedd5c6eea64bc1a19104fa1438a7bf8c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp divide in where analysts see real upside and where near-term catalysts could disappoint.",
                "category": "company",
                "datetime": 1791547208,
                "headline": "Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks"
              },
              {
                "id": 142792024,
                "url": "https://finnhub.io/api/news?id=f3a823dcaa1ad46254a0aaf4916bded17927ba986aa3a9285a4b9b916b36836d",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "UBS  analyst Michael Yee   maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.",
                "category": "company",
                "datetime": 1791545294,
                "headline": "UBS Maintains Neutral on AbbVie, Raises Price Target to $275"
              },
              {
                "id": 142756787,
                "url": "https://finnhub.io/api/news?id=ed23d7cec3f658bac0371cf92d89a162432240c7d2a84e75fed44e5f48a6a8dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
                "category": "company",
                "datetime": 1791540670,
                "headline": "2 Cash-Producing Stocks on Our Watchlist and 1 We Avoid"
              },
              {
                "id": 142763077,
                "url": "https://finnhub.io/api/news?id=d626c8c3007104bd568779ab4ab391c7ce954fe3b59d56a42ef059dcbbc34d01",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Guggenheim  analyst Vamil Divan   reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $288 price target.",
                "category": "company",
                "datetime": 1791537667,
                "headline": "Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target"
              },
              {
                "id": 142746922,
                "url": "https://finnhub.io/api/news?id=6d82d1f29b37c668501acad8a62716f96f7f57203f4aeb6c68105387e0eca70d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2273704999/image_2273704999.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "VYM's diversified portfolio positions it to benefit from the AI momentum, while HDV appeals to retirees seeking monthly income. Read more on VYM and HDV ETFs here.",
                "category": "company",
                "datetime": 1791514485,
                "headline": "VYM And HDV: Two Dividend ETFs That Complement Each Other"
              },
              {
                "id": 142738442,
                "url": "https://finnhub.io/api/news?id=f75e26b0729c5bff9494c60706fdff46e2e8753e7576109a0837be7c38c177d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer (PFE) stock has returned 17.5% over the past three months, easily outpacing the 3.7% return for the S&P 500. The board also just declared its 352nd quarterly dividend in a row. That reliable payout may be why many investors hold the shares, yet on Pfizer's latest earnings call, management was asked what it would take to cut that dividend. So what is Pfizer's management preparing for.",
                "category": "company",
                "datetime": 1791506167,
                "headline": "Should You Be Worried About Pfizer Stock?"
              },
              {
                "id": 142736104,
                "url": "https://finnhub.io/api/news?id=bff74f60d6f2160c55eb02e7e452a8c1637af7ee73d80472a98ad1b017bcc0e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Regeneron Pharmaceuticals (REGN) stock currently trades at 17.6 times earnings. That represents a notable discount to the 21.5 multiple of the median S&P 500 company. The shares have lost 4.1% over the past six months, trailing the 15.7% return of the broader index. Over twelve months, however, the stock returned 27% against the index's 17.1%. A valuation this low suggests investors are either overlooking a sound drug maker or pricing in underlying problems. So how healthy is the business you wo",
                "category": "company",
                "datetime": 1791505165,
                "headline": "What Is Going On With Regeneron Stock?"
              },
              {
                "id": 142763078,
                "url": "https://finnhub.io/api/news?id=8e4684bc1271f1c5aec3d7fb6e5203479dc06eb85948ae76eb63d90c98b5719e",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "JP Morgan  analyst Chris Schott   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $300.",
                "category": "company",
                "datetime": 1791478441,
                "headline": "JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300"
              },
              {
                "id": 142729808,
                "url": "https://finnhub.io/api/news?id=cfecdba559d9188cb658eba2eedbca983c8d2b838d0d76a1bf579ad858f1f60f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.",
                "category": "company",
                "datetime": 1791470820,
                "headline": "AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer"
              },
              {
                "id": 142727204,
                "url": "https://finnhub.io/api/news?id=0777919541fde067a3ae7f2057a4e37174b1a46ec3889aa06a812dc2cfa4d84e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Amgen (AMGN) stock has returned 44% over the past twelve months, easily outpacing the 17.1% gain for the S&P 500. Investors looking at that rally might question what catalysts remain to push shares higher. One candidate is an experimental therapy that is not yet on the market, and executives say its development is progressing rapidly. So what is that drug, and how far along is it.",
                "category": "company",
                "datetime": 1791464604,
                "headline": "What Would It Take For Amgen Stock To Move Higher?"
              },
              {
                "id": 142727205,
                "url": "https://finnhub.io/api/news?id=b9f422449f20b422638b049720516a8121f59c7b4b7cec48f8a6697c9914b67e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.",
                "category": "company",
                "datetime": 1791464400,
                "headline": "Pharma’s $500B patent problem will come in waves — not as a cliff"
              },
              {
                "id": 142724250,
                "url": "https://finnhub.io/api/news?id=674107ff4a129f2b03e7ec687e6c6b3035c3196e008a50605f5f78685a44f6f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Futures fell as oil prices and Treasury yields jumped. Samsung, Taiwan Semi results fall to cheer investors.",
                "category": "company",
                "datetime": 1791460288,
                "headline": "Dow Jones Futures Fall As Oil Prices, Treasury Yields Jump; Samsung, Micron, Taiwan Semi, Sandisk In Focus"
              },
              {
                "id": 142726900,
                "url": "https://finnhub.io/api/news?id=44ee6fd98adf9aec52c74e16d046374e97abb90a93bed87a45ec9e62693cd0fc",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $290.",
                "category": "company",
                "datetime": 1791441409,
                "headline": "Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290"
              },
              {
                "id": 142706903,
                "url": "https://finnhub.io/api/news?id=8269469ca71b3c9d3defbf538b21157e94a163e323b27ef79c6c12941e3c94b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The stock market cut losses as Treasury yields slashed gains. Samsung and Taiwan Semi news are relevant for Micron, Sandisk and more.",
                "category": "company",
                "datetime": 1791428115,
                "headline": "Dow Jones Futures: Yields Move Higher; Samsung, Micron, Taiwan Semi, Sandisk In Focus"
              },
              {
                "id": 142704791,
                "url": "https://finnhub.io/api/news?id=2129b638d75cef329d6d0fed6f2770fe6cf88efc77e2a3a953128cc6e1bc1dae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The stock market cut losses as Treasury yields slashed gains. Samsung and Taiwan Semi news are relevant for Micron, Sandisk and more.",
                "category": "company",
                "datetime": 1791423538,
                "headline": "Dow Jones Futures Fall As Yields Move Higher; Samsung, Micron, Taiwan Semi, Sandisk In Focus"
              },
              {
                "id": 142726901,
                "url": "https://finnhub.io/api/news?id=d91b2d8789706045cc92ff6706849593a085cb83d0e31acbf0af9d8ed49119eb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/08/Germany--Ludwigshafen--January-31--2025-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie Inc. Shares rose 0.44% after hours following FDA breakthrough designations for telisotuzumab adizutecan in two cancers.",
                "category": "company",
                "datetime": 1791413551,
                "headline": "Why is AbbVie (ABBV) Stock Trending After Hours?"
              },
              {
                "id": 142700277,
                "url": "https://finnhub.io/api/news?id=6980cc535c30123e751f7d600799ef0c4e6331fcd62f12d88ae5168a3b2648b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The stock market cut losses as Treasury yields slashed gains. Samsung and Taiwan Semi news will be key for Micron, Sandisk and more.",
                "category": "company",
                "datetime": 1791407652,
                "headline": "Dow Jones Futures: Stocks Pare Losses As Yields Back Off; Samsung, Micron, Taiwan Semi, Sandisk In Focus"
              },
              {
                "id": 142700258,
                "url": "https://finnhub.io/api/news?id=b5b5cee0eabc203182b64c219ab200fa5b1f4d2e3ded9d06b9d6f3715174bcdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The Dow Jones index drops 500 points Wednesday as Treasury yields jump. The Fed minutes are due later in the day.",
                "category": "company",
                "datetime": 1791407611,
                "headline": "Stock Market Today: S&P 500, Nasdaq Cut Losses; Nuclear Play Holds Firm"
              },
              {
                "id": 142700321,
                "url": "https://finnhub.io/api/news?id=77193bfeaac80c353a6ddb698c75fbb72f6b84e78e74bbbfa5d41b7083d85a41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson (NYSE:JNJ) is starting to look less like a defensive healthcare giant and more like a growth story. The harder question is how much investors should pay before that growth fully arrives. The company raised its 2026 outlook after second-quarter sales increased 6.6% to $25.3 billion. Adjusted EPS rose 4.7% to $2.90, while […]",
                "category": "company",
                "datetime": 1791407606,
                "headline": "Johnson & Johnson (JNJ) Is Becoming a Growth Stock. Does AbbVie (ABBV) Make JNJ Look Expensive?"
              },
              {
                "id": 142699343,
                "url": "https://finnhub.io/api/news?id=dfdf650e7cc8a91fd88dd02eee89a616b47dc77c4fa2c5a8d102e1f604903f92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 1.2% and the",
                "category": "company",
                "datetime": 1791402441,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 142699250,
                "url": "https://finnhub.io/api/news?id=69f89736d6b1ba81d734e7398bc3c5f814102bfd2e55fe2ec47378e8ee40e754",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The Dow Jones index drops 500 points Wednesday as Treasury yields jump. The Fed minutes are due later in the day.",
                "category": "company",
                "datetime": 1791401324,
                "headline": "Stock Market Today: S&P 500 Cuts Losses As Oil, Yields Drop But Caterpillar Shares Get Pounded (Live Coverage)"
              },
              {
                "id": 142697831,
                "url": "https://finnhub.io/api/news?id=683287b687d95e857a785c1de492dffd35b70d6ff8db3972eb817f9a09d627d2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "ABBV",
                "summary": "Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1791390901,
                "headline": "Wednesday's session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 142698403,
                "url": "https://finnhub.io/api/news?id=24cab9c3b44d655fea5e81162fe16de373b29b91fba1401c2a64dc187a69aaff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly (LLY) stock is priced at 38.7 times earnings, compared with 21.5 for the S&P 500. Investors evaluating that valuation should weigh what drives it, especially since the company's priorities have shifted. In late 2024, management opened its earnings call by detailing how many doses of its weight-loss and diabetes drugs it could manufacture. Today, the primary focus has broadened considerably beyond factory output. So what is it.",
                "category": "company",
                "datetime": 1791389636,
                "headline": "Why You Should Think About Eli Lilly Stock Differently Now"
              },
              {
                "id": 142697097,
                "url": "https://finnhub.io/api/news?id=aa96bd438f629403236b9e3e1bb680028b711cd0bbfc2008e5c540f0ef96ca1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar last quarter.",
                "category": "company",
                "datetime": 1791382529,
                "headline": "5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong"
              },
              {
                "id": 142697098,
                "url": "https://finnhub.io/api/news?id=61e95e09fac6363a5eaa08c22f74c820f964d3be9e2508819a124e32a4e0aa41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’",
                "category": "company",
                "datetime": 1791381480,
                "headline": "This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?"
              },
              {
                "id": 142697096,
                "url": "https://finnhub.io/api/news?id=19241232a1373b564a06423ce4e4c72f523955a757167948648b9d883cce44ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.",
                "category": "company",
                "datetime": 1791381420,
                "headline": "Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?"
              },
              {
                "id": 142694800,
                "url": "https://finnhub.io/api/news?id=0cb0291528fabe296f8b55180027c24a21f169e5f2f4c1c38d3f4f06a13e3aea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying the stock right now.",
                "category": "company",
                "datetime": 1791379822,
                "headline": "Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?"
              },
              {
                "id": 142694816,
                "url": "https://finnhub.io/api/news?id=a5c422844569817eb2e2a7c74b29861e9d1cb8e2cb4f3dcb06311289247d0b26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).",
                "category": "company",
                "datetime": 1791376200,
                "headline": "AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC"
              },
              {
                "id": 142696708,
                "url": "https://finnhub.io/api/news?id=6cb13c5c3477671749cc303924dbf8609d973a6c0413b64707490cdc5fb6734c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/07/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Two of 11 sectors are higher in Wednesday&#39;s regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with Health Care and Consumer Staples above the rest of the table.",
                "category": "company",
                "datetime": 1791370938,
                "headline": "9 Of 11 Sectors Fall Wednesday As Defensives Lead"
              },
              {
                "id": 142695821,
                "url": "https://finnhub.io/api/news?id=60cac798cb99ba05338b1459367d2fa4396c96c2ed9e67718f8a403cd217d977",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $296 to $310.",
                "category": "company",
                "datetime": 1791368418,
                "headline": "Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $310"
              },
              {
                "id": 142695822,
                "url": "https://finnhub.io/api/news?id=c851eea74e31c8bd9c68f2f1ecef0ab033ee39c668994b4fc6d613e46c9b90b9",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC)",
                "category": "company",
                "datetime": 1791362338,
                "headline": "AbbVie Receives Two New FDA's Breakthrough Therapy Designations For Telisotuzumab Adizutecan In Colorectal Cancer, Non-Small Cell Lung Cancer"
              },
              {
                "id": 142693339,
                "url": "https://finnhub.io/api/news?id=f9703e16cae6edb5f3c70178ad79c01fe87a4e4028c56998d119dba65fecc687",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217256698/image_2217256698.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Ironwood Pharmaceuticals' Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029. See why IRWD stock is a Buy now.",
                "category": "company",
                "datetime": 1791358766,
                "headline": "Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy"
              },
              {
                "id": 142683776,
                "url": "https://finnhub.io/api/news?id=cc9fe43742491130bc7483a556a15a5494c8d5fb34696b92439366d25aa12e5d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Genmab stock: what the latest trial results mean for investors Genmab (CPSE:GMAB) is suddenly back on many watchlists after two fresh clinical readouts in oncology, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large B cell lymphoma. The EPCORE DLBCL 2 trial, run with AbbVie, reported that epcoritamab plus R CHOP cut the risk of disease progression or death by 51% versus R CHOP alone in patients with higher risk DLBCL. For a late stage blood cancer study, that kind of...",
                "category": "company",
                "datetime": 1791357403,
                "headline": "Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?"
              },
              {
                "id": 142679114,
                "url": "https://finnhub.io/api/news?id=ecff9f7f3ab6a93edf19e34ec9a0f98b4ff15ecd7594c1989f6ee22afa42012d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 data for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The combination reduced the risk of disease progression or death by 51% versus standard R-CHOP alone, improving progression-free survival. The trial is the first Phase 3 study to show a meaningful benefit from a bispecific antibody in the frontline DLBCL setting. The epcoritamab and R-CHOP Phase 3 win in newly diagnosed DLBCL comes against a wider context...",
                "category": "company",
                "datetime": 1791349971,
                "headline": "AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%"
              },
              {
                "id": 142674599,
                "url": "https://finnhub.io/api/news?id=691bc26106592f4dda2beea3dec3cbbd41f19df27f5ffa0390cf22392b97e684",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) was trading at around $263 on October 5, up 14.18% over twelve months. Its payout ratio is 190.40%. The company distributes nearly twice what it reports as profit. A dividend that large is either about to be cut or is being paid out of something the earnings line does not show. READ […]",
                "category": "company",
                "datetime": 1791333195,
                "headline": "AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?"
              },
              {
                "id": 142667719,
                "url": "https://finnhub.io/api/news?id=a26ea685db2d69af258216ef057d2227ece5ede59ce9ceb7c62b75d5574368cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Treasuries now offer a yield that dividend investors once bragged about, which raises a question most retirees avoid asking: does an equity income portfolio actually come out ahead after risk, taxes, and inflation are factored in?",
                "category": "company",
                "datetime": 1791312200,
                "headline": "Forget Bonds: How Retirees Collect $6,650 a Month From Dividends Alone"
              },
              {
                "id": 142666669,
                "url": "https://finnhub.io/api/news?id=e647c0b7032ebacbbbc336adedfcc775fdd4d357e20ef62115e67373daff9ad4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "These stocks have tremendous businesses, and their valuations are incredibly low.",
                "category": "company",
                "datetime": 1791308101,
                "headline": "3 of the Best Growth Stocks to Buy in October 2026"
              },
              {
                "id": 142666678,
                "url": "https://finnhub.io/api/news?id=a5692eb89927e6afcce630219838f1afe82440790cb0eb9b56da4b166698442f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie.",
                "category": "company",
                "datetime": 1791308100,
                "headline": "HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English."
              },
              {
                "id": 142666762,
                "url": "https://finnhub.io/api/news?id=fe6ae46865f769881e764e4a73b5137cf3558be8ed757aff7630c27023576092",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly built its reputation on weight loss drugs, but a fast-growing portfolio in oncology, immunology, and neuroscience just posted triple-digit gains, and Wall Street is only beginning to price in what comes next.",
                "category": "company",
                "datetime": 1791306013,
                "headline": "Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss"
              },
              {
                "id": 142666778,
                "url": "https://finnhub.io/api/news?id=0881c60c3df2b7a8ffc046cb0548c8183d6fd43e5e16a635f18c2f87d77386a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The Danish biotech surged after its AbbVie-partnered Epkinly combination sharply reduced the risk of progression or death in newly diagnosed lymphoma patients.",
                "category": "company",
                "datetime": 1791304788,
                "headline": "Genmab’s Lymphoma Bet Delivers a 51% Knockout"
              },
              {
                "id": 142665557,
                "url": "https://finnhub.io/api/news?id=6ec39207a731a9f91a29467c17a0cd657d6bd7b3815a65da32a76780a7e0b0f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.",
                "category": "company",
                "datetime": 1791301320,
                "headline": "Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial"
              },
              {
                "id": 142667430,
                "url": "https://finnhub.io/api/news?id=8995a666ebf6b720d179c49695be772306a09407553d20fd984dd6644bc12b96",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2239308472/image_2239308472.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Click for more on GMAB stock.",
                "category": "company",
                "datetime": 1791299158,
                "headline": "Genmab: Epkinly Shines In Phase 3 DLBCL Trial"
              },
              {
                "id": 142665558,
                "url": "https://finnhub.io/api/news?id=2f72ce2b225993590072629e460994c4afbb9241e605ae740b3cb2d7bd0d69b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Recently published Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
                "category": "company",
                "datetime": 1791297060,
                "headline": "Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight"
              },
              {
                "id": 142665559,
                "url": "https://finnhub.io/api/news?id=49aeda10a9d9d9da0354aae87a8d7042faf8094af6e532d73f6a352de7e18d7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.",
                "category": "company",
                "datetime": 1791296520,
                "headline": "AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL"
              },
              {
                "id": 142665560,
                "url": "https://finnhub.io/api/news?id=5d4197b1a3b3227fcd4443f2b1459b805228e3142bb502bf93e66683fdcf6b6c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The healthcare company will release its third-quarter numbers later this month.",
                "category": "company",
                "datetime": 1791295802,
                "headline": "Should You Buy AbbVie Stock Before Oct. 30?"
              },
              {
                "id": 142662977,
                "url": "https://finnhub.io/api/news?id=a94fb58f1bc39299028dfa47644453f08b69879c1aa73aeb3a13ea968279018b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "When paychecks stop, the wrong income strategy forces you to sell shares at the worst possible moment. Five companies have raised their dividends through every recession and rate shock in modern memory, and together they turn a single portfolio into a reliable cash machine.",
                "category": "company",
                "datetime": 1791290978,
                "headline": "$100,000 in 5 Dividend Kings Will Generate Close to $4,000 Each Year Safely"
              },
              {
                "id": 142662975,
                "url": "https://finnhub.io/api/news?id=74914ed083742dc042df32ea139babad48dbf911c7366553ea6a1fcc8a905fab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1791289804,
                "headline": "Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?"
              },
              {
                "id": 142662976,
                "url": "https://finnhub.io/api/news?id=784b09eb8f6b4b949e770aeb48a66bcbaeee11c90f63547d1e7144704fd7df88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.",
                "category": "company",
                "datetime": 1791289548,
                "headline": "AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News"
              },
              {
                "id": 142694431,
                "url": "https://finnhub.io/api/news?id=fe085c43d75c231536307af547fccfc999b2c5d528a0fa054c33bffa9ffb8e8b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/06/Stock-Market-Trading-Chart-And-Analyzing.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Nine of 11 sectors are higher in Tuesday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Utilities well ahead of the next group.",
                "category": "company",
                "datetime": 1791286410,
                "headline": "9 Of 11 Sectors Rise In Tuesday Trading As Defensives Lead"
              },
              {
                "id": 142664872,
                "url": "https://finnhub.io/api/news?id=1626c4360c92b508d63f06ff42f842993b78c736f2beb5bd26dcdf1ae83e522c",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Scotiabank  analyst Louise Chen   maintains AbbVie (NYSE:ABBV) with a Sector Outperform and raises the price target from $280 to $320.",
                "category": "company",
                "datetime": 1791276302,
                "headline": "Scotiabank Maintains Sector Outperform on AbbVie, Raises Price Target to $320"
              },
              {
                "id": 142661071,
                "url": "https://finnhub.io/api/news?id=fa4e62d37773c7c6bf7edfded8ac67f1840aa06f98b57f83d4fc8eac3e94eab5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investing.com -- Shares of Genmab surged more than 8% in early trading Tuesday after the Danish biotech and AbbVie said their combination treatment for newly diagnosed patients with a type of lymphoma reduced the risk of disease progression or death in a late-stage study.",
                "category": "company",
                "datetime": 1791273124,
                "headline": "Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk"
              },
              {
                "id": 142655417,
                "url": "https://finnhub.io/api/news?id=5bfc3695b7d41d8bf0fa9cd8f682608fab4fb6c36a14ac07bd1a3e2c4420f4be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.",
                "category": "company",
                "datetime": 1791272880,
                "headline": "Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?"
              },
              {
                "id": 142639169,
                "url": "https://finnhub.io/api/news?id=435d2c1c1401e8e129688ebe5c3d2780cfe2cd5de255c16a58c0f15ddca7e961",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed.",
                "category": "company",
                "datetime": 1791233123,
                "headline": "AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender"
              },
              {
                "id": 142639168,
                "url": "https://finnhub.io/api/news?id=a81024099cdb8b60a44184fbd31a1738de94d9d3272011da488792ab3fbeb7f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) closed at $265.85 in the latest trading session, marking a +1.15% move from the prior day.",
                "category": "company",
                "datetime": 1791233104,
                "headline": "Why AbbVie (ABBV) Outpaced the Stock Market Today"
              },
              {
                "id": 142638412,
                "url": "https://finnhub.io/api/news?id=f67e2b4e34bae463f7b6e958597b4c300db91a1576378fb816d545ce10673f37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie and Medtronic are both stable blue chip dividend plays in this choppy market.",
                "category": "company",
                "datetime": 1791228900,
                "headline": "Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October"
              },
              {
                "id": 142638477,
                "url": "https://finnhub.io/api/news?id=217fe5071e6a252c80bb6a5008675277346d7962e87f1ab7d9b33436c8c61ce2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investing.com -- Genmab A/S (NASDAQ:GMAB) shares rose 11% Monday afternoon following the announcement of positive topline results from a Phase 3 trial of epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma patients.",
                "category": "company",
                "datetime": 1791228561,
                "headline": "Genmab stock surges 11% on positive cancer drug trial data"
              },
              {
                "id": 142638473,
                "url": "https://finnhub.io/api/news?id=a0aed603f70bc8ef264d79f324d24d5701ee850ef739f8229b152e269fcdd855",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Key TakeawaysAbbVie yields 2. 7% and Merck 2.",
                "category": "company",
                "datetime": 1791227027,
                "headline": "Better Dividend for Retirees: AbbVie vs. Merck"
              },
              {
                "id": 142638474,
                "url": "https://finnhub.io/api/news?id=a3da2e9b317f70ff8cea67488d035b4038319d606a78219fe638aaef7de0b86b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Progn",
                "category": "company",
                "datetime": 1791226440,
                "headline": "AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma"
              },
              {
                "id": 142638475,
                "url": "https://finnhub.io/api/news?id=bde88342c77d38321802747a34a7a6dc0351ca1b4198f4477b26aa7f7ef85c83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patientsBased on the topline results, Genmab and AbbVie will engage global regulatory authorities Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announce",
                "category": "company",
                "datetime": 1791226140,
                "headline": "Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma"
              },
              {
                "id": 142664873,
                "url": "https://finnhub.io/api/news?id=df667b52f1fd1f45f5993f5202da5861e3aea9dbaee0cc3d91ea5978e39a2cce",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody",
                "category": "company",
                "datetime": 1791212102,
                "headline": "Genmab, AbbVie Announce Data From Phase 3 EPCORE DLBCL-2 Study Of Epcoritamab Demonstrates Reduction In Disease Progression, Death By 51% For Large B-Cell Lymphoma"
              },
              {
                "id": 142636798,
                "url": "https://finnhub.io/api/news?id=02b55fb819eac16ad9dadcdcb5f78fd4425f22a5be3f5f3a3aaf11e2f425c375",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "One thing stands out at Eli Lilly (LLY): how many prescriptions are written for Zepbound and Mounjaro, which may be what buyers are betting on. You may think of them as high-priced drugs, but their U.S. prices are now falling. Yet the stock costs 38.2 times earnings, against 21.5 for the S&P 500. That is the tension. So, how much are the two drugs actually selling.",
                "category": "company",
                "datetime": 1791209955,
                "headline": "Has Eli Lilly Stock Peaked?"
              },
              {
                "id": 142635019,
                "url": "https://finnhub.io/api/news?id=cfda9a1448e16e56d0851bc582ecf1656ddd25118451560d36a286cecccd10d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "LLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.",
                "category": "company",
                "datetime": 1791204360,
                "headline": "FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting"
              },
              {
                "id": 142632130,
                "url": "https://finnhub.io/api/news?id=11de99ccd4b911af68f3aefc385255c817bc8bc17c5e164b2485144c4d06292a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Key Stats for AbbVie StockCurrent Price: $262. 82Target Price (Mid): ~$362Street Target: ~$279Potential Total Return: ~38%Annualized IRR: ~8% / yearWhat Happened?AbbVie (ABBV:NYSE) has two pricing events landing on the same day.",
                "category": "company",
                "datetime": 1791187719,
                "headline": "AbbVie Announced Its 340B Rebate Pilot on October 2. Here’s What It Means for the Stock Before Vraylar’s 2027 Medicare Price Cut"
              },
              {
                "id": 142627993,
                "url": "https://finnhub.io/api/news?id=bb63323a7ff767b443ec70481139d1628ba1c405dbff07dda9e5ee287fdde519",
                "image": "",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1791155223,
                "headline": "ExxonMobil, Visa Among 16 Dividend Growth Companies To Announce Annual Dividend Increases In October"
              },
              {
                "id": 142618515,
                "url": "https://finnhub.io/api/news?id=acedf7ae2285dee254393203d1a2bcb489bd28de60e87f8af56da1e7e1c98e0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something new, before the revenue disappeared. AbbVie is widely seen as having pulled it off and […]",
                "category": "company",
                "datetime": 1791081989,
                "headline": "AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?"
              },
              {
                "id": 142616069,
                "url": "https://finnhub.io/api/news?id=55954dbd5e187414527860bcc88f6f4e54f863aa5f71e51a6801960d3f3ae228",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Three blue-chip dividend stocks sitting in a taxable account hand a portion of every payout straight to the IRS, but the account type holding them changes that math completely. Here is what the numbers actually look like across every tax bracket.",
                "category": "company",
                "datetime": 1791054044,
                "headline": "This 3-Stock Roth Portfolio Pays $25,849 a Year Without a Federal Tax Bill"
              },
              {
                "id": 142615634,
                "url": "https://finnhub.io/api/news?id=7496c1f33c01476aee148b5bcda2e3403de430e63c148d98e44da2e0dc1017e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "From a pharma giant rebuilding after a blockbuster patent loss to a pipeline partnership targeting double-digit distribution raises through 2027, these five stocks span wildly different industries yet share one thing: cash flow that keeps covering the check.",
                "category": "company",
                "datetime": 1791045938,
                "headline": "5 High-Yield Dividend Stocks to Buy for October Income with Cash Flow to Spare"
              },
              {
                "id": 142624150,
                "url": "https://finnhub.io/api/news?id=7e2cb675536c0c9b14dc0f8ac39311049b0a11e1b60c46a7ab6ab60875ed1795",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.",
                "category": "company",
                "datetime": 1791038700,
                "headline": "3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note"
              },
              {
                "id": 142610572,
                "url": "https://finnhub.io/api/news?id=2aed46a52d7ccc92d236aa340c090f03f9a9a5aa7c92ca1fdae73b35deef0b82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Another potential blockbuster just joined AbbVie's drug portfolio.",
                "category": "company",
                "datetime": 1791022200,
                "headline": "AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think."
              },
              {
                "id": 142594334,
                "url": "https://finnhub.io/api/news?id=c6ec2f723c48ab5b0c4d50b17c06956a336fdffe5d38fc9a055d99b262272ca8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Successful stock investors have one thing in common: the power of compounding.",
                "category": "company",
                "datetime": 1790977200,
                "headline": "How to Create a Million-Dollar Stock Portfolio"
              },
              {
                "id": 142592789,
                "url": "https://finnhub.io/api/news?id=ca4d7e53fbbed91317e2344999af050e978e4beb6f546949df13bc82d18582d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Replacing a $160,000 salary with dividends at 58 sounds like a single math problem, but the required portfolio swings by millions depending on which yield tier you choose, and the tier that demands the least capital up front carries a hidden cost that grows every year.",
                "category": "company",
                "datetime": 1790969996,
                "headline": "How Much Does a 58-Year-Old Need Invested to Replace a $160,000 Salary With Dividends?"
              },
              {
                "id": 142614487,
                "url": "https://finnhub.io/api/news?id=ad5a102f0f462f0b122ae780f777417e58a4dbfe929a821a4af06a8778848ecf",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "https://news.abbvie.com/2026-10-02-AbbVie-to-Participate-in-Federal-340B-Rebate-Model-Pilot",
                "category": "company",
                "datetime": 1790956797,
                "headline": "AbbVie To Participate In Federal 340b Rebate Model Pilot"
              },
              {
                "id": 142588420,
                "url": "https://finnhub.io/api/news?id=3e9acb61c8beb0770b8746219d57ea06bd2a725b259e6bcf4015e587d2ae1091",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.",
                "category": "company",
                "datetime": 1790946032,
                "headline": "Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker"
              },
              {
                "id": 142590792,
                "url": "https://finnhub.io/api/news?id=510ff0cf1c37661401ef523a1a0e96744fe98ab89cc4cc962cc7fdea3fb87a06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.",
                "category": "company",
                "datetime": 1790946000,
                "headline": "Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?"
              },
              {
                "id": 142588430,
                "url": "https://finnhub.io/api/news?id=6d010eb7ec552adf9cf2d8123c73e1a7f1896ededdb70c290de2c2b3673c63d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "JNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.",
                "category": "company",
                "datetime": 1790944200,
                "headline": "J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch"
              },
              {
                "id": 142590478,
                "url": "https://finnhub.io/api/news?id=f3811fb0268670d0a3fadaa1f32444c29b09a67de3d3d33d9abb18b71da84971",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Friday&#39;s regular session has eight sectors higher and three lower, with growth sectors holding two of the top three positions. The leaders are clustered, with less than a quarter-point separating the top three sectors.",
                "category": "company",
                "datetime": 1790938892,
                "headline": "8 Of 11 Sectors Rise Friday As Growth Leads"
              },
              {
                "id": 142585466,
                "url": "https://finnhub.io/api/news?id=67bda7f26ae04d0d3f35078b1e3e515457b65d707cb614ee0369159ab7b04c5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.",
                "category": "company",
                "datetime": 1790936840,
                "headline": "How Has Pfizer's Story Changed?"
              },
              {
                "id": 142563714,
                "url": "https://finnhub.io/api/news?id=e98e6cb8cdda4ddef333d043a63b0f58a5549656408252b35331ef9926a27d67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.",
                "category": "company",
                "datetime": 1790894462,
                "headline": "AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142563711,
                "url": "https://finnhub.io/api/news?id=3dcdf33e534bab68fda8cc2a95917363b4617f0b04646dacb6c634e5c6e52e0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.",
                "category": "company",
                "datetime": 1790892781,
                "headline": "Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?"
              },
              {
                "id": 142560859,
                "url": "https://finnhub.io/api/news?id=1004675a3080c500140879e91c85cb59144d85989ca6b71efb090de0653da551",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie has delivered a powerful 187.5% total return over the past 5 years, so the current US$261.59 share price naturally raises a question for investors who care about cash generation. With fresh drug approvals, pipeline updates and new partnerships in the headlines, the key issue now is whether AbbVie’s cash flows are strong enough and durable enough to underpin where the stock trades today. That 187.5% 5 year return puts real pressure on the valuation question, because a move of that size...",
                "category": "company",
                "datetime": 1790874723,
                "headline": "AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval"
              },
              {
                "id": 142560839,
                "url": "https://finnhub.io/api/news?id=a696a9ab0cb6ff5270642859a717ad049d9ca3139724748a7a10c5143b396ab1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.",
                "category": "company",
                "datetime": 1790871360,
                "headline": "3 takeaways from a European obesity scientific meeting"
              },
              {
                "id": 142560840,
                "url": "https://finnhub.io/api/news?id=e1c08e4bbb8e459a2d7b192134c7bdddeb78f099fdf34d930fe361886eba3ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.",
                "category": "company",
                "datetime": 1790869272,
                "headline": "What Is The Options Market Telling Us About Eli Lilly Stock?"
              },
              {
                "id": 142559734,
                "url": "https://finnhub.io/api/news?id=3f247beaf74ed05d1e097c1bda9cf4966e57f533f70751b976b7fff4b7c706d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.",
                "category": "company",
                "datetime": 1790863200,
                "headline": "AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo"
              },
              {
                "id": 142560597,
                "url": "https://finnhub.io/api/news?id=26f7032aba1266a905c4dfd11a725fa060f8b98d79d3b5c820bfc4664cff3528",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1152284409/image_1152284409.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Regeneron and Sanofi expand antibody pact targeting IL-4/IL-13 inflammation therapies, with $1B upfront and up to $7B milestones. Click to read my analysis for more.",
                "category": "company",
                "datetime": 1790861390,
                "headline": "Regeneron And Sanofi Announce A Win-Win Collaboration Expansion"
              },
              {
                "id": 142557735,
                "url": "https://finnhub.io/api/news?id=d5ff87426f42ed66416c92785b6f8227551d76c891ddf7e7cceb550be11ba136",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Five dividend payers across four sectors promise to keep raising payouts through the next downturn, but one of them carries a GAAP payout ratio above 100% and a negative book value that would alarm most income investors at first glance.",
                "category": "company",
                "datetime": 1790860740,
                "headline": "5 Solid Dividend Stocks to Buy Now"
              },
              {
                "id": 142557749,
                "url": "https://finnhub.io/api/news?id=6d1799363718529e4e522f3ff1a18293912a24e26ec6e666ac102ca716affc8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1790856007,
                "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 142557705,
                "url": "https://finnhub.io/api/news?id=fc02df4ca81bbf563aba38753308faab25f82a8a451afecd5ea23577ce412d8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
                "category": "company",
                "datetime": 1790856000,
                "headline": "AbbVie to Host Third-Quarter 2026 Earnings Conference Call"
              },
              {
                "id": 142556540,
                "url": "https://finnhub.io/api/news?id=2d6dc8a2b35359397c4e4fa84b895092a419ca82bea88c427d0173f8855a5464",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the screen?",
                "category": "company",
                "datetime": 1790853359,
                "headline": "5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)"
              },
              {
                "id": 142557734,
                "url": "https://finnhub.io/api/news?id=299273e9cf56ccf03c135ac8c65f16b744b9d9e4c0c821df08ace4cb4fb03f5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.",
                "category": "company",
                "datetime": 1790853060,
                "headline": "ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?"
              },
              {
                "id": 142558991,
                "url": "https://finnhub.io/api/news?id=a33aa8ff0bd6036b88046a4849adcc0b874197107fa047110e2c29eee62be2a8",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial",
                "category": "company",
                "datetime": 1790849059,
                "headline": "AbbVie Presents Data From Its Current Phase 3 Viti-Up-1, Viti-Up-2 Trials Of RINVOQ At 2026 European Academy Of Dermatology And Venereology Congress"
              },
              {
                "id": 142522943,
                "url": "https://finnhub.io/api/news?id=c747aebba32eb636e3b57420d8499423e7bbb2b046a2042871b0d126d296b891",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.",
                "category": "company",
                "datetime": 1790794880,
                "headline": "Was The Run In JNJ Stock Hiding In Plain Sight?"
              },
              {
                "id": 142521902,
                "url": "https://finnhub.io/api/news?id=3708b38ab40282a8ceb0ded2061e018c6747d0fc1616ece434791f7aac72513e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The pharmaceutical giant still looks like a stable long-term investment.",
                "category": "company",
                "datetime": 1790787000,
                "headline": "AbbVie Stock: Buy, Sell, or Hold in October?"
              },
              {
                "id": 142559721,
                "url": "https://finnhub.io/api/news?id=297d7b9403786f1da6e4a279a0d6546a8726b21dbc06e1562265d42c1bc0020f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.",
                "category": "company",
                "datetime": 1790782500,
                "headline": "3 Healthcare Dividend Stocks Offering More Than Just Income"
              },
              {
                "id": 142520808,
                "url": "https://finnhub.io/api/news?id=72a16884875e8205de3652d0399aae55c3f3a4b916c99485ad73dc7a499774f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.",
                "category": "company",
                "datetime": 1790782145,
                "headline": "Are You Overpaying For Pfizer Stock Versus Its Rivals?"
              },
              {
                "id": 142520832,
                "url": "https://finnhub.io/api/news?id=9e649824e2e5e0725e57f418d60c8af485afa67a9662a84fa0696c93d0ee8d2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) reported Phase 2 APEX Part B data for zumilokibart in moderate to severe atopic dermatitis at the EADV Congress. The company selected a mid dose of zumilokibart for Phase 3 development after the study showed significant clinical improvements in patients. AbbVie joined the Antibody Developability Consortium as a founding member and started a new AI driven R&D collaboration with Valkai. The zumilokibart Phase 2 results and AbbVie’s new AI alliances matter, but investors...",
                "category": "company",
                "datetime": 1790781012,
                "headline": "What Does AbbVie (ABBV) Need To Prove After Its Eczema Drug And AI Update?"
              },
              {
                "id": 142520809,
                "url": "https://finnhub.io/api/news?id=76d46d09777c71c504574fbb4fc04c17977db7ccfaa9d0806d18f0f7f44a6972",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.",
                "category": "company",
                "datetime": 1790779413,
                "headline": "What Is Merck Stock's Biggest Opportunity?"
              },
              {
                "id": 142520833,
                "url": "https://finnhub.io/api/news?id=292e645b0c10c6442c43024f4629fee89622526051f7f80a79f3aca631f0c9cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.",
                "category": "company",
                "datetime": 1790777880,
                "headline": "PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval"
              },
              {
                "id": 142516927,
                "url": "https://finnhub.io/api/news?id=9867c237e44c2f4997a2ee2fc47bd07c7a171bdeb1f22a933c9a97684c09935e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- \"Drug Repurposing Market - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra",
                "category": "company",
                "datetime": 1790775600,
                "headline": "Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson"
              },
              {
                "id": 142514807,
                "url": "https://finnhub.io/api/news?id=03ee06748e8ca0eab8461d479385a65e20c3001aae6bdec2f37763c81546b155",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
                "category": "company",
                "datetime": 1790771353,
                "headline": "1 Profitable Stock to Keep an Eye On and 2 Facing Challenges"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 250,
            "discarded_article_count": 221
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19.8,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.1,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(13.1%→7.4%)；站上MA50；升放量(近10日5日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 4860446.666666667,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 5523230,
              "avg_vol_20": 5197405,
              "avg_vol_30": 4860446.666666667,
              "range_pct_10": 0.07358909558923488,
              "range_pct_20": 0.11738548111659847,
              "range_pct_30": 0.13121407606728488,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 5,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1363626388246895,
              "dist_to_20d_high": 0.01976657583275821,
              "down_shrink_days": 2,
              "breakout_level_20d": 291.39999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.5608323267962451
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.541660742835011,
              "turnoverUsdM": 1322.8274503110001,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.ABBV",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 271.12,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.1,
            "take_profit_price": 300.8134,
            "target_multiplier": 1.9,
            "technical_strength": 1.65,
            "take_profit_percent": 5.3
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.083321485670022,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.ABBV",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 7.26,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.54
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 77.35
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1398
    },
    "kdj": {
      "d": 74.57,
      "j": 63.86,
      "k": 71,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 57.22
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 52383100,
      "recentSlope": 478490,
      "previousSlope": 2708380
    },
    "rsi": 70.88,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 291.1322,
      "position": "SAR喺價上",
      "distancePct": 1.92,
      "previousTrend": "下降"
    },
    "ma50": 266.1246,
    "macd": {
      "macd": 6.499774495198778,
      "trend": "強烈看漲",
      "signal": 5.804682373074317,
      "histogram": 0.6950921221244615
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 275.1959,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 16
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.87,
      "score": 4,
      "avgVolume": 5301940,
      "currentVolume": 4631100
    },
    "derived": {
      "ma20": 275.089,
      "ma50": 266.1246,
      "prevClose": 285.19,
      "avgVolume10": 5556600,
      "avgVolume20": 5301940,
      "changePercent": 0.16,
      "avgVolumeForScore": 5301940
    },
    "ma_cross": {
      "ma20": 275.089,
      "ma50": 266.1246,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 274.024,
      "prevMa50": 265.4282,
      "spreadPct": 3.37,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 256.0942,
      "upper": 294.0838,
      "position": "上半部"
    },
    "rsi_short": 56.88,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.87
    }
  }
}

{
  "close": 285.64,
  "volume": 4631100,
  "changePercent": 0.16
}